<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravenous iron therapy for non‐anaemic, iron‐deficient adults - Miles, LF - 2019 | Cochrane Library</title> <meta content="Intravenous iron therapy for non‐anaemic, iron‐deficient adults - Miles, LF - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013084.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravenous iron therapy for non‐anaemic, iron‐deficient adults - Miles, LF - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013084.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013084.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravenous iron therapy for non‐anaemic, iron‐deficient adults" name="citation_title"/> <meta content="Lachlan F Miles" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="lachlan.miles@unimelb.edu.au" name="citation_author_email"/> <meta content="Edward Litton" name="citation_author"/> <meta content="Fiona Stanley Hospital" name="citation_author_institution"/> <meta content="Georgina Imberger" name="citation_author"/> <meta content="Rigshospitalet" name="citation_author_institution"/> <meta content="David Story" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD013084.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013084.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013084.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013084.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Iron Deficiencies; Hemoglobins [*metabolism]; Infusions, Intravenous; Iron [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013084.pub2&amp;doi=10.1002/14651858.CD013084.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013084\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013084\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","fa","pl","fr","zh_HANS","de","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013084.pub2",title:"Intravenous iron therapy for non\\u2010anaemic, iron\\u2010deficient adults",firstPublishedDate:"Dec 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013084.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013084.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013084.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013084.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013084.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013084.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013084.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013084.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013084.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013084.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7763 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013084.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/appendices#CD013084-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/table_n/CD013084StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/table_n/CD013084StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravenous iron therapy for non‐anaemic, iron‐deficient adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#CD013084-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lachlan F Miles</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#CD013084-cr-0003">Edward Litton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#CD013084-cr-0004">Georgina Imberger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information#CD013084-cr-0005">David Story</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information/en#CD013084-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013084.pub2">https://doi.org/10.1002/14651858.CD013084.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013084-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013084-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013084-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013084-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013084-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013084-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013084-abs-0001" lang="en"> <section id="CD013084-sec-0001"> <h3 class="title" id="CD013084-sec-0001">Background</h3> <p>Iron deficiency is one of the most common nutritional deficiencies, and has a number of physiological manifestations. Early, or non‐anaemic iron deficiency can result in fatigue and diminished exercise capacity. Oral iron preparations have a high incidence of intolerable side effects, and are ineffective in certain forms of iron deficiency. Consequently, intravenous iron preparations are increasingly used in the treatment of non‐anaemic iron deficiency. The newer, more stable iron preparations in particular purport to have a lower incidence of side effects, and are now used across a range of different patient populations. </p> </section> <section id="CD013084-sec-0002"> <h3 class="title" id="CD013084-sec-0002">Objectives</h3> <p>To assess the effects of intravenous iron therapy in the treatment of adults with non‐anaemic iron deficiency. </p> </section> <section id="CD013084-sec-0003"> <h3 class="title" id="CD013084-sec-0003">Search methods</h3> <p>On 18 October 2019 we electronically searched CENTRAL, MEDLINE, Embase, two further databases and two trials registries 2019. We handsearched the references of full‐text extracted studies, and contacted relevant study authors for additional data. </p> </section> <section id="CD013084-sec-0004"> <h3 class="title" id="CD013084-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials that compared any intravenous iron preparation to placebo in adults. We excluded other forms of comparison such as oral iron versus placebo, intramuscular iron versus placebo, or intravenous iron studies where other iron preparations were used as the comparator. We also excluded studies involving erythropoietin therapy or obstetric populations. </p> </section> <section id="CD013084-sec-0005"> <h3 class="title" id="CD013084-sec-0005">Data collection and analysis</h3> <p>Two review authors screened references for eligibility, extracted data and assessed risk of bias. We resolved differences in opinion through discussion and consensus, and where necessary, involved a third review author to adjudicate disputes. We contacted study authors to request additional data where appropriate. The primary outcome measures were haemoglobin concentration at the end of follow‐up, and quality‐of‐life scores at end of follow‐up. Secondary outcome measures were serum ferritin, peak oxygen consumption (as measured by cardiopulmonary exercise testing), adverse effects (graded as mild to moderate and severe) and bacterial infection. We pooled data for continuous outcomes, which we then reported as mean differences (MDs) with 95% confidence intervals (CIs). We reported quality‐of‐life metrics as standardised mean difference (SMD), and then converted them back into a more familiar measure, the Piper Fatigue Scale. We analysed dichotomous outcomes as risk ratios (RRs). Given an expected degree of heterogeneity, we used a random‐effects model for all outcomes. We performed the analysis with the software package Review Manager 5. </p> </section> <section id="CD013084-sec-0006"> <h3 class="title" id="CD013084-sec-0006">Main results</h3> <p>This review includes 11 studies with 1074 participants. Outcome metrics for which data were available (haemoglobin concentration, quality‐of‐life scores, serum ferritin, peak oxygen consumption and mild to moderate adverse effects) were similar across the included studies. The incidence of severe adverse events across all studies was zero. None of the studies measured bacterial infection as a specific outcome metric. </p> <p>Substantial heterogeneity influenced the results of the meta‐analysis, arising from differing patient populations, definitions of iron deficiency, iron preparations and dosing regimens, and time to end of follow‐up. Consequently, many outcomes are reported with small group sizes and wide confidence intervals, with a subsequent downgrading in the quality of evidence. The level of bias in many included studies was high, further reducing confidence in the robustness of the results. </p> <p>We found that intravenous iron therapy may lead to a small increase in haemoglobin concentration of limited clinical significance compared to placebo (MD 3.04 g/L, 95% CI 0.65 to 5.42; I<sup>2</sup> = 42%; 8 studies, 548 participants; low‐quality evidence). Quality‐of‐life scores (Piper Fatigue Scale MD 0.73, 95% CI 0.29 to 1.18; I<sup>2</sup> = 0%; studies = 3) and peak oxygen consumption (MD 2.77 mL/kg/min, 95% CI −0.89 to 6.43; I<sup>2</sup> = 36%; 2 studies, 32 participants) were associated with very low‐quality evidence, and we remain uncertain about the role of intravenous iron for these metrics. We were unable to present pooled estimates for the outcomes of serum ferritin at the end of follow‐up or mild to moderate adverse effects due to extreme statistical heterogeneity. Ultimately, despite the results of the meta‐analysis, the low‐ or very low‐quality evidence for all outcomes precludes any meaningful interpretation of results beyond suggesting that further research is needed. We performed a Trial Sequential Analysis for all major outcomes, none of which could be said to have reached a necessary effect size. </p> </section> <section id="CD013084-sec-0007"> <h3 class="title" id="CD013084-sec-0007">Authors' conclusions</h3> <p>Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non‐anaemic iron deficiency across a variety of patient populations, beyond stating that it may result in a small, clinically insignificant increase in haemoglobin concentration. However, the certainty for even this outcome remains limited. Robust data for the effectiveness of intravenous iron for non‐anaemic iron deficiency is still lacking, and larger studies are required to assess the effect of this therapy on laboratory, patient‐centric, and adverse‐effect outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013084-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013084-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013084-abs-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013084-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013084-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013084-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013084-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013084-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013084-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013084-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013084-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013084-abs-0004" lang="en"> <h3>Intravenous iron for the treatment of non‐anaemic iron deficiency in adults</h3> <p><b>Background</b> </p> <p>Iron deficiency, when the body does not have enough of the mineral iron, is a common, nutritional deficiency. Iron is used by the body to make haemoglobin, a protein in red blood cells that enables them to carry oxygen around the body. Whilst iron deficiency is most commonly associated with a low level of haemoglobin in the blood (anaemia), early, or 'non‐anaemic' iron deficiency can also lead to symptoms such as tiredness and lack of energy. Non‐anaemic iron deficiency is often treated with oral iron, which is medicine taken by mouth, such as iron tablets. However, oral iron is likely to cause side effects, is not effective for certain types of iron deficiency, and takes time to work fully. In addition, newer iron preparations, such as intravenous iron, are more stable, have fewer side effects and have maximum benefit in a shorter time period. </p> <p><b>Aim of the review</b> </p> <p>To review the evidence from randomised controlled trials (where people are allocated a treatment at random) on the safety and effects of intravenous iron in the treatment of early, or non‐anaemic iron deficiency. </p> <p><b>Study characteristics</b> </p> <p>We found 11 studies with 1074 participants. A broad range of people were included in these studies, including people with heart failure, elite athletes, people with restless legs syndrome and otherwise fit and well women. We excluded studies that looked at children, pregnant women, and people being treated with erythropoietin (a hormone that stimulates the production of red blood cells). </p> <p><b>Key results</b> </p> <p>Intravenous iron may lead to a small increase in the level of haemoglobin in the blood. We also assessed the effect of intravenous iron on quality of life, serum ferritin (iron stored in the body), peak exercise capacity, and milder side‐effects of iron administration but we were unable to determine whether or not intravenous iron was of benefit for these outcomes. This is because there were many differences between studies in the types of participants studied, the definition of iron deficiency used, the type of intravenous iron preparation prescribed and the length of the studies. We also tried to collect data on severe side effects and bacterial infection after iron infusion, but we were unable to find any studies that measured these effectively. </p> <p><b>Certainty of the evidence</b> </p> <p>Because of the many differences between the relatively small number of studies included in this review, we are uncertain about the effect of intravenous iron in non‐anaemic iron deficiency beyond saying that it might cause an increase in haemoglobin concentration. Furthermore, the starting level of haemoglobin for people included in this review was considered 'normal' prior to their receiving treatment. Therefore, not only is this increase quite small, but the starting level of haemoglobin was considered adequate according to current guidance, and patients may not even notice an improvement in symptoms. We are not suggesting that intravenous iron is not of benefit for adults with non‐anaemic iron deficiency, rather that the current quality of evidence is not good enough to be certain about the effects of these drugs. </p> <p><b>Conclusions</b> </p> <p>Overall, the evidence for intravenous iron for the treatment of non‐anaemic iron deficiency is of low or very low quality. Whilst intravenous iron might cause a small increase in haemoglobin concentration from an already normal level, we are uncertain about its effects in other outcomes that we examined as part of this review. Further research examining the effects of intravenous iron for the treatment of adults with non‐anaemic iron deficiency is required to help answer this research question. </p> <p>The evidence is current to October 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013084-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013084-sec-0108"></div> <h3 class="title" id="CD013084-sec-0109">Implications for practice</h3> <section id="CD013084-sec-0109"> <p>Despite the recommendation for the use of intravenous iron in non‐anaemic, iron‐deficient adults in best practice guidelines (particularly in perioperative medicine (<a href="./references#CD013084-bbs2-0095" title="MuñozM , AchesonAG , AuerbachM , BesserM , HablerI , KehletH , et al. International consensus statement on the peri‐operative management of anaemia and iron deficiency. Anaesthesia2017;72:233‐47. ">Muñoz 2017</a>; <a href="./references#CD013084-bbs2-0096" title="National Blood Authority. Module 2: Perioperative. Patient Blood Management Guidelines2012. ">National Blood Authority 2012</a>), our review finds that the evidence underpinning these recommendations is limited. There is low‐quality evidence that intravenous iron may result in a small, clinically insignificant increase in haemoglobin concentration, but the evidence for our other outcomes of interest (ferritin concentration, quality‐of‐life scores, exercise capacity) is of very low quality so we are unable to draw conclusions about these outcomes. Methodological heterogeneity with respect to inconsistent definitions of iron deficiency and anaemia make it difficult to determine which patient populations are likely to benefit from this intervention, or if benefit can be expected at all. </p> </section> <h3 class="title" id="CD013084-sec-0110">Implications for research</h3> <section id="CD013084-sec-0110"> <p>This review highlights the poor quality of evidence for intravenous iron therapy in non‐anaemic, iron‐deficient adults across a range of laboratory and patient‐centred outcome measures, and a range of different patient populations. Further good‐quality data from randomised controlled trials (RCTs) are required to determine the validity of existing best practice recommendations for the routine correction of non‐anaemic iron deficiency. However, prior to this occurring, it is necessary to more clearly define iron deficiency, and so determine which populations are likely to derive maximum benefit. Certainly, for patients with concomitant inflammation or medical comorbidities, the use of serum ferritin in isolation is potentially problematic, due to loss of discrimination for the detection of iron deficiency. In the context of treatment with intravenous iron, this point is important, as those patients with functional iron deficiency are less likely to respond to oral iron, and will theoretically derive increased benefit from parenteral therapy. With increased awareness of the important role of hepcidin in the pathogenesis of functional iron deficiency, it is likely that future definitions will include this, and other research tools, such as soluble transferrin receptor, as part of defining iron deficiency. Future RCTs should take note of this during planning so as to better contextualise their results in this evolving field. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013084-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013084-sec-0036"></div> <div class="table" id="CD013084-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous iron compared to placebo for non‐anaemic, iron‐deficient adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous iron compared to placebo for non‐anaemic iron deficient adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐anaemic, iron‐deficient adults<br/> <b>Setting:</b> all healthcare settings (acute, subacute and community care)<br/> <b>Intervention:</b> intravenous iron<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intravenous iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin concentration</b> taken at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin concentration taken at the end of follow‐up was 131.93 g/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.04 g/L higher<br/> (0.65 higher to 5.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous iron may result in a slight, clinically insignificant increase in haemoglobin concentration taken at the end of follow‐up, but the evidence is limited. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall quality of life</b> measured at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall quality of life measured at the end of follow‐up was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Piper Fatigue Scale MD 0.73 lower (0.29 to 1.18 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on overall quality of life measured at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin</b> concentration measured at the end of follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>We were unable to perform meta‐analysis for this outcome due to substantial statistical heterogeneity (I<sup>2</sup> = 100%). In all 7 studies a we observed a higher ferritin concentration in the intervention group relative to the control </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on serum ferritin at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bacterial infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peak oxygen consumption</b> taken at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean peak oxygen consumption taken at the end of follow‐up was 25.89 mL/kg/min</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.77 mL/kg/min higher<br/> (0.89 lower to 6.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on peak oxygen consumption taken at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies reported any serious adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mild adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/> (0.97 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>440<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain about the effect of intravenous iron on mild to moderate adverse effects taken at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>402 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>478 per 1,000<br/> (390 to 583) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for inconsistency: there was moderate statistical heterogeneity and multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up.<br/> <sup>2</sup>Downgraded one level for imprecision: the confidence interval around the point prevalence estimate of effect is wide, and on Trial Sequential Analysis, the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power.<br/> <sup>3</sup>Downgraded one level for risk of bias: none of the included studies were at low risk of bias, and we judged the largest included study to be at high risk of bias from multiple protocol deviations and no reporting of the per protocol analysis.<br/> <sup>4</sup>Downgraded one level for inconsistency: despite mild or negligible statistical heterogeneity, we observed multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up.<br/> <sup>5</sup>Downgraded two levels for inconsistency: there was substantial statistical heterogeneity in the pooled result (I<sup>2</sup> = 100%) and multiple points of methodological heterogeneity, with dose of iron administered and time to end of follow‐up.<br/> <sup>6</sup>Downgraded two levels for imprecision: the point prevalence estimates in each of the included studies are highly imprecise, as reflected by the large confidence interval of the total result. The generated effect size is considerably less than the required effect size calculated by Trial Sequential Analysis.<br/> <sup>7</sup>Downgraded one level for risk of bias: one of the two included studies was at high risk of bias for participant blinding. The outcome in question could potentially be compromised by performance bias.<br/> <sup>8</sup>Downgraded two levels for imprecision: the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. There is considerable difference in the mean difference in the two included studies.<br/> <sup>9</sup>Downgraded one level for imprecision: on Trial Sequential Analysis, the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013084-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013084-sec-0037"></div> <section id="CD013084-sec-0038"> <h3 class="title" id="CD013084-sec-0038">Description of the condition</h3> <p>Elemental iron is ubiquitous in the biosphere and has been incorporated into the essential physiological processes of many organisms, including humans (<a href="./references#CD013084-bbs2-0049" title="AbbaspourN , HurrellR , KelioshadiR . Review on iron and its importance for human health. Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences2014;19:164‐74. [PUBMED: 24778671] ">Abbaspour 2014</a>). Depletion of bodily iron stores has a number of manifestations, with profound physiological consequences. The most recognised complication of iron deficiency is anaemia, as the lack of iron results in failure of haemoglobin production (<a href="./references#CD013084-bbs2-0116" title="World Health Organization, United Nations University, UNICEF . Iron deficiency anemia: assessment, prevention and control. A guide for programme managers. WHO2001; Vol. www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/, issue (accessed 24 July 2018). ">WHO 2001</a>). However, anaemia is effectively the final stage of iron deficiency, and early forms of the disease can be of detriment to physical health and well‐being, with fatigue, diminished mental acuity, reductions in work capacity and productivity, and reduced exercise tolerance all being reported in the literature (<a href="./references#CD013084-bbs2-0093" title="MusallamKM , TaherAT . Iron deficiency beyond erythropoiesis: should we be concerned?. Current Medical Research and Opinion2018;34(1):81‐93. ">Musallam 2018</a>). </p> <p>The identification and management of iron deficiency (particularly early, or non‐anaemic iron deficiency) is made challenging by different forms of the disease. Broadly speaking, iron deficiency takes the following two forms (<a href="./references#CD013084-bbs2-0068" title="GoodnoughLT . Iron deficiency syndromes and iron‐restricted erythropoesis. Transfusion2012;52:1584‐92. ">Goodnough 2012</a>). </p> <p> <ol id="CD013084-list-0001"> <li> <p>Absolute iron deficiency: this refers to the absence of sufficient iron stores to maintain effective erythropoiesis (<a href="./references#CD013084-bbs2-0067" title="GoodnoughLT , NemethE , GanzT . Detection, evaluation and management of iron‐restricted erythropoesis. Network2011;116:4754‐61. ">Goodnough 2011</a>; <a href="./references#CD013084-bbs2-0103" title="PasrichaSR , DrakesmithH , BlackJ , HipgraveD , BiggsB . Control of iron deficiency anaemia in low and middle income countries. Blood2013;121:2607‐17. ">Pasricha 2013</a>). This is normally due to increased requirements in excess of stored iron, decreased intake of dietary iron, increased red cell loss or decreased absorption of dietary iron (<a href="./references#CD013084-bbs2-0097" title="NelsonM , BakaliouF , TrivediA . Iron‐deficiency anaemia and physical performance in adolescent girls from different ethnic backgrounds. British Journal of Nutrition1994;72:427‐33. ">Nelson 1994</a>; <a href="./references#CD013084-bbs2-0105" title="ReveizL , GyteGM , CuervoLG , CasabuenasA . Treatments for iron‐deficiency anaemia in pregnancy. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD003094.pub3] ">Reveiz 2011</a>). The condition is not associated with a derangement in iron regulatory or erythropoietic mechanisms. </p> </li> <li> <p>Functional iron deficiency: this exists where, despite an apparently adequate store, iron cannot be effectively mobilised to participate in erythropoiesis (<a href="./references#CD013084-bbs2-0102" title="PasrichaS , Flecknoe‐BrownSC , AllenKJ , GibsomPR , McMahonLP , OlynykJK , et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Medical Journal of Australia2010;193:525‐32. ">Pasricha 2010</a>). Understanding the pathophysiology of functional iron deficiency was greatly enhanced by the discovery of the 25‐amino acid peptide, hepcidin (<a href="./references#CD013084-bbs2-0053" title="BeardJL . Iron biology in immune function, muscle metabolism and neuronal functioning. Journal of Nutrition2001;131:S568‐80. ">Beard 2001</a>; <a href="./references#CD013084-bbs2-0062" title="DrakesmithH , PrenticeAM . Hepcidin and the iron‐infection axis. Science2012;338:768‐72. ">Drakesmith 2012</a>; <a href="./references#CD013084-bbs2-0064" title="GanzT . Hepcidin, a key regulator of iron metabolism and mediator of anaemia of inflammation. Blood2003;102:783‐8. ">Ganz 2003</a>; <a href="./references#CD013084-bbs2-0067" title="GoodnoughLT , NemethE , GanzT . Detection, evaluation and management of iron‐restricted erythropoesis. Network2011;116:4754‐61. ">Goodnough 2011</a>; <a href="./references#CD013084-bbs2-0079" title="JordanJB , PoppeL , HaniuM , ArvedsonT , SyedR , LiV , et al. Hepcidin revisited, disulphide connectivity, dynamics and structure. Journal of Biological Chemistry2009;284:24155‐67. ">Jordan 2009</a>; <a href="./references#CD013084-bbs2-0083" title="KrauseA , NeitzS , MagertHJ , SchulzA , ForssmannWG , Schulz‐KnappeP , et al. LEAP‐1, a novel highly disulphide‐bonded peptide, exhibits antimicrobial activity. FESB Letters2000;480:147‐50. ">Krause 2000</a>; <a href="./references#CD013084-bbs2-0098" title="NemethE , RiveraS , GavatanV , KellerC , TaudorfS , PedersenBK , et al. IL‐6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation2004;113:1271‐6. ">Nemeth 2004a</a>; <a href="./references#CD013084-bbs2-0099" title="NemethE , TuttleMS , PowelsonJ , VaughnMB , DonovanA , WardDM , et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science2004;306:2090‐3. ">Nemeth 2004b</a>; <a href="./references#CD013084-bbs2-0101" title="ParkCH , ValoreEV , WaringAJ , GanzT . Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of Biological Chemistry2001;276:7806‐10. ">Park 2001</a>; <a href="./references#CD013084-bbs2-0114" title="WeissG , GoodnoughLT . Anaemia of Chronic Disease. New England Journal of Medicine2005;352:1011‐32. ">Weiss 2005</a>). </p> </li> </ol> </p> <p>In a healthy person, simple indices of iron status such as ferritin (a storage form of iron predominantly found in the liver, which is detectable in serum as it leaks into the circulation) and transferrin saturation (percentage occupation of iron carrier molecules in the circulation) are sufficient to diagnose iron deficiency (<a href="./references#CD013084-bbs2-0084" title="LimJ , MilesLF , LittonE . Intravenous iron therapy in patients undergoing cardiovascular surgery: a narrative review. Journal of Cardiothoracic and Vascular Anesthesia2018;32(3):1439‐51. ">Lim 2018</a>). However, in the setting of inflammation, ferritin acts as an acute‐phase reactant and serum concentration increases, meaning interpretation of ferritin alone as a measure of iron deficiency becomes unreliable. Simultaneously, in response to the same inflammatory process that makes serum ferritin difficult to interpret, a 25‐amino acid protein is produced, known as hepcidin. The functions of hepcidin are two‐fold: </p> <p> <ol id="CD013084-list-0002"> <li> <p>prevention of iron overload through limiting excessive iron absorption in the proximal small intestine and regulation of iron release from macrophages participating in recycling (<a href="./references#CD013084-bbs2-0064" title="GanzT . Hepcidin, a key regulator of iron metabolism and mediator of anaemia of inflammation. Blood2003;102:783‐8. ">Ganz 2003</a>), and; </p> </li> <li> <p>prevention of iron acquisition by pathogens as a component of innate immunity (<a href="./references#CD013084-bbs2-0083" title="KrauseA , NeitzS , MagertHJ , SchulzA , ForssmannWG , Schulz‐KnappeP , et al. LEAP‐1, a novel highly disulphide‐bonded peptide, exhibits antimicrobial activity. FESB Letters2000;480:147‐50. ">Krause 2000</a>). </p> </li> </ol> </p> <p>Hepcidin impairs the function of the key iron regulatory protein, ferroportin, thereby preventing the transport of iron across basement membranes (<a href="./references#CD013084-bbs2-0098" title="NemethE , RiveraS , GavatanV , KellerC , TaudorfS , PedersenBK , et al. IL‐6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation2004;113:1271‐6. ">Nemeth 2004a</a>). This inhibits the uptake of iron from the gastrointestinal tract, the transport of stored iron out of the liver, and the reclamation of iron from circulating macrophages. Whilst serum levels of ferritin appear high, iron is unable to circulate or be delivered to the bone marrow, which in turn leads to iron‐restricted erythropoiesis (<a href="./references#CD013084-bbs2-0114" title="WeissG , GoodnoughLT . Anaemia of Chronic Disease. New England Journal of Medicine2005;352:1011‐32. ">Weiss 2005</a>). There is increasing evidence that ferritin is a key modulator of the inflammasome, and that this increased ferritin seen in inflammation may be an active player in innate immunity, as opposed to a consequence of cell damage and leakage (<a href="./references#CD013084-bbs2-0080" title="KellDB , PretoriusE . Serum ferritin is an important inflammatory disease marker as it is mainly a leakage product from damaged cells. Metallomics2014;6:748‐73. ">Kell 2014</a>). </p> <p>Estimation of the incidence of iron deficiency is difficult, as many clinicians will only think to perform iron studies after first making a diagnosis of anaemia. In the perioperative context, iron deficiency in one form or another is relatively common, affecting 35% to 37% of cardiac surgical patients (<a href="./references#CD013084-bbs2-0089" title="MilesLF , KunzSA , NaLH , BraatS , BurburyK , StoryDA . Postoperative outcome following cardiac surgery in non‐anaemic iron‐replete and iron‐deficient patients ‐ an exploratory study. Anaesthesia2018;73(4):450‐8. ">Miles 2018a</a>; <a href="./references#CD013084-bbs2-0108" title="RösslerJ , SchoenrathF , SeifertB , KasererA , SpahnGH , FalkV , et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. British Journal of Anaesthesia Vol. (in press). ">Rössler 2019</a>), and an even higher proportion of colorectal surgical patients (<a href="./references#CD013084-bbs2-0090" title="MilesLF , SandhuRN , GroblerAC , HeritierS , BurgessA , BurburyKL , et al. Associations between non‐anaemic iron deficiency and outcomes following surgery for colorectal cancer: an exploratory study of outcomes relevant to prospective observational studies. Anaesthesia and Intensive Care2019;47(2):152‐9. ">Miles 2019a</a>). In the context of heart failure, 50% of patients are affected by iron deficiency (<a href="./references#CD013084-bbs2-0113" title="vonHaehlingS , EbnerN , EvertzR , PonikowskiP , AnkerSD . Iron deficiency in heart failure: an overview. JACC: Heart Failure2019;7(1):36‐46. ">von Haehling 2019</a>), although an estimate of the relative proportions between anaemic and non‐anaemic is not possible for the reasons previously stated. In a recent audit of hospital inpatients with heart failure and anaemia, only 29% had an appropriate assessment of iron status, suggesting that the appropriate assessment of non‐anaemic patients is likely to be even poorer (<a href="./references#CD013084-bbs2-0110" title="SimonS , IaonnouA , DeorajS , MetaxaS , MendalAK , MissourisCG . Audit of the prevalence and investigation of iron deficiency anaemia in patients with heart failure in hospital practice. Postgraduate Medical Journal Vol. (in press). ">Simon 2019</a>). An overall estimate of non‐anaemic iron deficiency across every patient population, and the distribution between absolute and functional iron deficiency cannot be given at this time, although upcoming prospective work in a variety of populations will likely be useful in providing much needed demographic data. </p> </section> <section id="CD013084-sec-0039"> <h3 class="title" id="CD013084-sec-0039">Description of the intervention</h3> <p>In this systematic review, we have investigated intravenous iron therapy as an intervention for non‐anaemic, iron‐deficient adults. Current guidelines recommend oral iron as the first line of treatment for people who are iron‐deficient. However, oral iron therapy is associated with some issues relating to compliance and efficacy. </p> <p> <ol id="CD013084-list-0003"> <li> <p>Oral iron may result in gastrointestinal side effects, meaning that adherence to therapy may be poor (<a href="./references#CD013084-bbs2-0058" title="Cancelo‐HidalgoMJ , Castelo‐BrancoC , PalaciosS , Haya‐PalazuelosJ , Ciria‐RecasensM , ManasanchJ , et al. Tolerability of different oral iron supplements: a systematic review. Current Medical Research and Opinion2013;29(4):291‐303. ">Cancelo‐Hidalgo 2013</a>; <a href="./references#CD013084-bbs2-0066" title="GerekliogluC , AsmaS , KorurA , ErdoganF , KutA . Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pakistani Journal of Medical Science2016;32:604‐7. ">Gereklioglu 2016</a>). Whilst recent research findings have suggested alternate or third daily dosing strategies may minimise side effects (<a href="./references#CD013084-bbs2-0111" title="StoffelN , CercamondiCI , BrittenhamG , ZederC , Geurts‐MoespotAJ , SwinkelsDW . Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice‐daily split dosing in iron‐depleted women: two open‐label, randomised controlled trials. Lancet Haematology2017;4(11):E524‐33. ">Stoffel 2017</a>), current guidelines still recommend daily dosing. </p> </li> <li> <p>Use of oral therapy does not lead to rapid incorporation of iron into the body. This is especially true in functional iron deficiency, where inflammation prevents the transport of iron across the enterocyte due to the activity of the hepcidin‐ferroportin axis (<a href="./references#CD013084-bbs2-0068" title="GoodnoughLT . Iron deficiency syndromes and iron‐restricted erythropoesis. Transfusion2012;52:1584‐92. ">Goodnough 2012</a>; <a href="./references#CD013084-bbs2-0098" title="NemethE , RiveraS , GavatanV , KellerC , TaudorfS , PedersenBK , et al. IL‐6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation2004;113:1271‐6. ">Nemeth 2004a</a>; <a href="./references#CD013084-bbs2-0099" title="NemethE , TuttleMS , PowelsonJ , VaughnMB , DonovanA , WardDM , et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science2004;306:2090‐3. ">Nemeth 2004b</a>; <a href="./references#CD013084-bbs2-0100" title="NemethE , GanzT . The role of hepcidin in iron metabolism. Acta Hematologica2009;122:78‐86. ">Nemeth 2009</a>). </p> </li> <li> <p>Correction of haemoglobin levels using oral therapy alone may be slow, sometimes requiring weeks of therapy until substantive gains are made, and gains may be attenuated by ongoing blood loss (<a href="./references#CD013084-bbs2-0059" title="CançadoRD , MuñozM . Intravenous iron therapy. Revista Brasileira de Hematologia e Hemoterapia2011;33:461‐9. ">Cançado 2011</a>; <a href="./references#CD013084-bbs2-0078" title="Johnson‐WimbleyTD , GrahamDY . Diagnosis and management of iron deficiency anemia in the 21st century. Therapeutic Advances in Gastroenterology2011;4:177‐84. ">Johnson‐Wimbley 2011</a>). This is of particular relevance in the urgent surgery population, where emerging evidence is beginning to suggest a contribution of non‐anaemic iron deficiency to poor post‐operative outcome (<a href="./references#CD013084-bbs2-0089" title="MilesLF , KunzSA , NaLH , BraatS , BurburyK , StoryDA . Postoperative outcome following cardiac surgery in non‐anaemic iron‐replete and iron‐deficient patients ‐ an exploratory study. Anaesthesia2018;73(4):450‐8. ">Miles 2018a</a>; <a href="./references#CD013084-bbs2-0090" title="MilesLF , SandhuRN , GroblerAC , HeritierS , BurgessA , BurburyKL , et al. Associations between non‐anaemic iron deficiency and outcomes following surgery for colorectal cancer: an exploratory study of outcomes relevant to prospective observational studies. Anaesthesia and Intensive Care2019;47(2):152‐9. ">Miles 2019a</a>; <a href="./references#CD013084-bbs2-0108" title="RösslerJ , SchoenrathF , SeifertB , KasererA , SpahnGH , FalkV , et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. British Journal of Anaesthesia Vol. (in press). ">Rössler 2019</a>), and hence a more rapid correction of iron status may be desirable (<a href="./references#CD013084-bbs2-0095" title="MuñozM , AchesonAG , AuerbachM , BesserM , HablerI , KehletH , et al. International consensus statement on the peri‐operative management of anaemia and iron deficiency. Anaesthesia2017;72:233‐47. ">Muñoz 2017</a>). </p> </li> </ol> </p> <p>These issues are avoided by giving iron through the intravenous route. By bypassing the hepcidin‐ferroportin axis, the treatment has an improved clinical effect in the setting of inflammation, and does not have the same gastrointestinal side effects of oral iron. Consequently, intravenous iron preparations are being used more widely for patients who, under previous guidelines, would not have received this therapy as first‐line treatment (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). Previously, parenteral iron preparations were highly labile and prone to the excessive release of free iron into the circulation, with an associated risk of side effects (<a href="./references#CD013084-bbs2-0051" title="BailieGR . Comparison of rates of reported adverse events associated with I.V. iron products in the United States. American Journal of Health‐System Pharmacy2012;69(4):310‐20. ">Bailie 2012</a>). However, the development of newer, high‐molecular‐weight and more stable preparations has markedly reduced the incidence of these events (<a href="./references#CD013084-bbs2-0050" title="AvniT , BieberA , GrossmanA , GreenH , LeiboviciL , Gafter‐GviliA . The safety of intravenous iron preparations: systematic review and meta‐analysis. Mayo Clinic Proceedings2015;90:12‐23. ">Avni 2015</a>). Consequently, administration of parenteral iron is becoming more widespread. </p> </section> <section id="CD013084-sec-0040"> <h3 class="title" id="CD013084-sec-0040">How the intervention might work</h3> <p>Iron therapy has been increasingly advocated in a variety of clinical scenarios including perioperative optimisation of haemoglobin (<a href="./references#CD013084-bbs2-0060" title="ClevengerB , MallettSV , KleinAA , RichardsT . Patient blood management to reduce surgical risk. British Journal of Surgery2015;102:1325‐37. ">Clevenger 2015</a>). Iron is a limiting factor to oxygen transport and storage when iron is insufficient for erythropoiesis (<a href="./references#CD013084-bbs2-0065" title="GanzT , NemethE . Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harbor Perspectives in Medicine2012;2:1‐14. ">Ganz 2012</a>). Iron deficiency may also affect adenosine triphosphate (ATP) production and increase the predominance of energy production towards anaerobic sources, such as anaerobic glycolysis (<a href="./references#CD013084-bbs2-0073" title="HintonPS . Iron and the endurance athlete. Applied Physiology, Nutrition and Metabolism2014;39:1012‐8. ">Hinton 2014</a>; <a href="./references#CD013084-bbs2-0088" title="MelenovskyV , PetrakJ , MracekT , BenesJ , BorlaugBA , NuskovaH , et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. European Journal of Heart Failure2017;19:522‐30. ">Melenovsky 2016</a>). </p> <p>Accordingly, even in the absence of anaemia, insufficient iron stores may have non‐haematological effects that are detrimental to health, well‐being and functional status (<a href="./references#CD013084-bbs2-0093" title="MusallamKM , TaherAT . Iron deficiency beyond erythropoiesis: should we be concerned?. Current Medical Research and Opinion2018;34(1):81‐93. ">Musallam 2018</a>). This hypothesis has been tested in people with heart failure, where insufficient iron stores are associated with impaired exercise performance, increased fatigue and reduced health‐related quality of life (<a href="./references#CD013084-bbs2-0077" title="JankowskaEA , TkaczyszynM , SuchockiT , DrozdM , vonHaehlingS , DoehnerW , et al. Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials. European Journal of Heart Failure2016;18(7):786‐95. ">Jankowska 2016</a>; <a href="./references#CD013084-bbs2-0082" title="KlipIT , Comin‐ColetJ , VoorsAA , PonikowskiP , EnjuanesC , BanasiakW , et al. Iron deficiency in chronic heart failure: an international pooled analysis. American Heart Journal2013;165:575‐82. ">Klip 2013</a>). In this setting, administration of iron therapy may improve symptoms. </p> <p>As noted previously, oral iron therapy for the treatment of iron deficiency has several limitations related to efficacy and compliance, particularly when oral supplements are administered daily. The use of intravenous iron in scenarios where a rapid response is required (such as the individual undergoing urgent surgery), or where inflammation is present, is considered preferable. It has been hypothesised that the administration of large amounts of intravenous iron, and subsequent overload of the reticuloendothelial capacity for iron, leads to a transient and compensatory reduction in hepcidin expression, allowing replenishment of iron stores through export from the plasma (<a href="./references#CD013084-bbs2-0059" title="CançadoRD , MuñozM . Intravenous iron therapy. Revista Brasileira de Hematologia e Hemoterapia2011;33:461‐9. ">Cançado 2011</a>). </p> </section> <section id="CD013084-sec-0041"> <h3 class="title" id="CD013084-sec-0041">Why it is important to do this review</h3> <p>It has been recognised for some time that iron deficiency is a staged process, and that anaemia, whilst the most recognisable manifestation of this pathology, effectively represents the end stage of the disease (<a href="./references#CD013084-bbs2-0112" title="SuominenP , PunnonenK , RajamäkiA , IrjalaK . Serum transferrin receptor and transferrin receptor‐ferritin index identify healthy subjects with subclinical iron deficits. Blood1998;92:2934‐9. ">Suominen 1998</a>). Observational studies from different populations have highlighted the impact of the pathology on exercise performance and fatigue (<a href="./references#CD013084-bbs2-0052" title="Barberan‐GarciaA , RodríguezDA , BlancoI , GeaJ , TorralbaY , Arbillaga‐EtxarriA , et al. Non‐anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD. Respirology2015;20:1089‐95. ">Barberan‐Garcia 2015</a>; <a href="./references#CD013084-bbs2-0104" title="PrattJJ , KhanKS . Non‐anaemic iron deficiency ‐ a disease looking for recognition of diagnosis: a systematic review. European Journal of Haematology2016;96(6):618‐28. [DOI: 10.1111/ejh.12645] ">Pratt 2016</a>), as well as the benefits of correction (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). Recently, a number of perioperative guidelines and consensus statements have advocated for the correction of iron deficiency in people about to undergo major surgery (<a href="./references#CD013084-bbs2-0096" title="National Blood Authority. Module 2: Perioperative. Patient Blood Management Guidelines2012. ">National Blood Authority 2012</a>; <a href="./references#CD013084-bbs2-0095" title="MuñozM , AchesonAG , AuerbachM , BesserM , HablerI , KehletH , et al. International consensus statement on the peri‐operative management of anaemia and iron deficiency. Anaesthesia2017;72:233‐47. ">Muñoz 2017</a>). </p> <p>Pathological organisms also rely on iron for key functions. It is increasingly recognised that certain regulatory processes in the body exist to reduce the availability of free iron in the circulation at times of inflammation and infection (<a href="./references#CD013084-bbs2-0062" title="DrakesmithH , PrenticeAM . Hepcidin and the iron‐infection axis. Science2012;338:768‐72. ">Drakesmith 2012</a>; <a href="./references#CD013084-bbs2-0064" title="GanzT . Hepcidin, a key regulator of iron metabolism and mediator of anaemia of inflammation. Blood2003;102:783‐8. ">Ganz 2003</a>; <a href="./references#CD013084-bbs2-0100" title="NemethE , GanzT . The role of hepcidin in iron metabolism. Acta Hematologica2009;122:78‐86. ">Nemeth 2009</a>). It has been postulated that administration of parenteral iron to bypass these regulatory mechanisms may lead to an increased risk of bacterial infection (<a href="./references#CD013084-bbs2-0062" title="DrakesmithH , PrenticeAM . Hepcidin and the iron‐infection axis. Science2012;338:768‐72. ">Drakesmith 2012</a>). Evidence for this effect is conflicting. A systematic review in hospital inpatients found a 33% increased risk of infection where parenteral iron was administered (<a href="./references#CD013084-bbs2-0085" title="LittonE , XiaoJ , HoKM . Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta‐analysis of randomised clinical trials. BMJ Open2013;347(August):f4822. ">Litton 2013</a>), but this is not reflected in large, retrospective cohort analyses (<a href="./references#CD013084-bbs2-0094" title="MuñozM , Gõmez‐RamírezS , CuencaJ , García‐ErceJA , Iglesias‐AparicioD , Haman‐AlcoberS , et al. Very‐short‐term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion2014;54:289‐99. ">Muñoz 2014</a>), or other meta‐analyses examining the safety of newer, high‐molecular‐weight iron preparations (<a href="./references#CD013084-bbs2-0050" title="AvniT , BieberA , GrossmanA , GreenH , LeiboviciL , Gafter‐GviliA . The safety of intravenous iron preparations: systematic review and meta‐analysis. Mayo Clinic Proceedings2015;90:12‐23. ">Avni 2015</a>; <a href="./references#CD013084-bbs2-0107" title="RognoniC , VenturiniS , MeregagliaM , MarmiferoM , TarriconeR . Efficacy and safety of ferric carboxymaltose and other formulations in iron‐deficient patients: a systematic review and network meta‐analysis of randomised controlled trials. Clinical Drug Investigation2016;36:177‐94. ">Rognoni 2016</a>). Evidence from developing countries suggests that population‐based interventions to address the high incidence of nutritional iron deficiency concomitantly increased the incidence of infectious diseases (<a href="./references#CD013084-bbs2-0103" title="PasrichaSR , DrakesmithH , BlackJ , HipgraveD , BiggsB . Control of iron deficiency anaemia in low and middle income countries. Blood2013;121:2607‐17. ">Pasricha 2013</a>). </p> <p>Given these apparent conflicts, we perceived a need for further clarification of the role of iron therapy to treat non‐anaemic iron deficiency. There are several reasons to assess the effects of intravenous iron on the correction of non‐anaemic iron deficiency across patient groups: </p> <p> <ol id="CD013084-list-0004"> <li> <p>the current definition of anaemia in the non‐pregnant adult is not dependent on the presence or absence of comorbidities and is based on historical expert consensus (<a href="./references#CD013084-bbs2-0057" title="ButcherA , RichardsT , StanworthSJ , KleinAA . Diagnostic criteria for pre‐operative anaemia–time to end sex discrimination. Anaesthesia2017;72:811‐4. ">Butcher 2017</a>); </p> </li> <li> <p>a haemoglobin concentration above the historical threshold for anaemia may still be clinically important, particularly for women (<a href="./references#CD013084-bbs2-0055" title="BlaudszunG , MuntingKE , ButchartA , GerrardC , KleinAA . The association between borderline pre‐operative anaemia in women and outcome after cardiac surgery: a cohort study. Anaesthesia2018;73(5):572‐8. ">Blaudszun 2018</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0091" title="MilesLF , LarsenT , BaileyMJ , BurburyKL , StoryDA , BellomoR . Borderline anaemia and postoperative outcome in women undergoing major abdominal surgery: a retrospective cohort study. Anaesthesia Vol. (in press). ">Miles 2019b</a>); </p> </li> <li> <p>intravenous iron therapy for people with anaemia is associated with an increase in haemoglobin in a wide variety of clinical scenarios; </p> </li> <li> <p>in patients undergoing major surgery, a higher haemoglobin at the start of operation has been shown to be the only correctable factor protecting against allogeneic blood transfusion (<a href="./references#CD013084-bbs2-0081" title="KleinAA , CollierT , YeatesJ , MilesLF , FletcherSN , EvansC . The ACTA PORT‐score for predicting perioperative risk of blood transfusion for adult cardiac surgery. British Journal of Anaesthesia2017;119(3):394‐401. [DOI: 10.1093/bja/aex205] ">Klein 2017</a>); </p> </li> <li> <p>iron depletion may have pronounced metabolic effects, even in the absence of anaemia, particularly with respect to fatigue and cognition (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>); and </p> </li> <li> <p>iron depletion (even in the absence of anaemia) worsens the functional capacity (and the effect of corrective interventions) of a variety of different patient populations (<a href="./references#CD013084-bbs2-0052" title="Barberan‐GarciaA , RodríguezDA , BlancoI , GeaJ , TorralbaY , Arbillaga‐EtxarriA , et al. Non‐anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD. Respirology2015;20:1089‐95. ">Barberan‐Garcia 2015</a>; <a href="./references#CD013084-bbs2-0104" title="PrattJJ , KhanKS . Non‐anaemic iron deficiency ‐ a disease looking for recognition of diagnosis: a systematic review. European Journal of Haematology2016;96(6):618‐28. [DOI: 10.1111/ejh.12645] ">Pratt 2016</a>). </p> </li> </ol> </p> <p>There is yet to be a systematic review determining the aggregate effect of intravenous iron therapy in isolation on features of iron deficiency other than anaemia. This review has the potential to substantially guide practice in this evolving area, where intravenous iron therapy is increasingly being used for the management of non‐anaemic iron deficiency. A high‐quality summary of the evidence is required to adequately inform practice, and direct the development of future randomised controlled trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013084-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013084-sec-0042"></div> <p>To assess the effects of intravenous iron therapy in the treatment of adults with non‐anaemic iron deficiency. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013084-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013084-sec-0043"></div> <section id="CD013084-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013084-sec-0045"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) for inclusion in this review. We included RCTs irrespective of blinding, language of publication, publication status, date of publication, study setting or sample size. We did not include quasi‐randomised trials, cross‐over trials or other non‐RCT designs. We considered quasi‐randomised trials to be any controlled trial where the method of allocation was not truly random (i.e. allocation based on medical record number, date of birth, day of week, etc.). We considered cluster‐randomised trials for inclusion if the method of randomisation was truly random (i.e. random number sequence, coin flip, etc.). We excluded cross‐over trials as we felt this was an inappropriate design to assess this intervention. </p> </section> <section id="CD013084-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included all adults (18 years and above) with functional or absolute non‐anaemic iron deficiency. Non‐anaemia was defined as haemoglobin (Hb) greater than 130 g/L for men and greater than 120 g/L for non‐pregnant women. Studies that did not differentiate a Hb between men and women, and set a non‐anaemic definition of greater than 120 g/L for both sexes were also included. </p> <p>In order to capture the broadest possible population, we reviewed a series of RCTs from the existing literature to define iron deficiency, and chose the least restrictive definition (<a href="./references#CD013084-bbs2-0054" title="Beck‐da‐SilvaL , PiardiD , SodlerS , RohdeLE , Pereira‐BarrettoAC , deAlbuquerqueD , et al. IRON‐HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology2013;168:3439‐42. ">Beck‐da‐Silva 2013</a>). We defined iron deficiency as: </p> <p> <ol id="CD013084-list-0005"> <li> <p>absolute iron deficiency: ferritin less than 100 µg/L;</p> </li> <li> <p>functional iron deficiency: ferritin more than 100 µg/L and transferrin saturation (TSAT) less than 20%. </p> </li> </ol> </p> <p>We excluded pregnant and puerperal women because of considerable differences in the definition of anaemia in pregnancy. We also excluded studies from paediatric populations. </p> <p>We excluded participants who were treated with erythropoietin or other erythropoiesis‐stimulating agents (ESA) alone or in combination with iron. </p> </section> <section id="CD013084-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We considered any study comparing any formulation of intravenous iron with placebo. We considered all doses and preparations of intravenous iron. We excluded oral iron preparations from the review because the therapeutic benefit of oral iron is difficult to assess due to the presence of multiple confounding factors (principally poor compliance due to side effects, or malabsorption due to concomitant inflammation or duodenal pathology). We feared that this would introduce substantial and unquantifiable heterogeneity into the analysis, especially as the included studies would cover a wide range of patient populations, some of which, by definition, would be unable to take oral iron. In order to adequately assess the biological effect of iron loading across multiple patient groups, we necessarily excluded oral iron interventions. </p> </section> <section id="CD013084-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD013084-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013084-list-0006"> <li> <p>Haemoglobin concentration (g/L), measured at the end of follow‐up</p> </li> <li> <p>Overall quality of life, taken at the end of follow‐up, as measured by a quantitative quality‐of‐life measurement scale </p> </li> </ol> </p> <p>The outcomes chosen reflected key quantitative and qualitative endpoints for this intervention. Quality‐of‐life scoring systems have the ability to assess the clinical effects of iron replenishment separate from changes in haemoglobin concentration. There is considerable controversy in this area, particularly with respect to existing definitions of anaemia and evidence of continued haemoglobin response to iron replenishment despite haemoglobin concentration being apparently 'normal' (<a href="./references#CD013084-bbs2-0057" title="ButcherA , RichardsT , StanworthSJ , KleinAA . Diagnostic criteria for pre‐operative anaemia–time to end sex discrimination. Anaesthesia2017;72:811‐4. ">Butcher 2017</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). We used an assessment of both a laboratory parameter of response to iron therapy (haemoglobin concentration) and quality‐of‐life metrics to determine if observed improvements with iron therapy in previous studies are related to improvements in haemoglobin concentration or another, as yet undefined metric. </p> </section> <section id="CD013084-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013084-list-0007"> <li> <p>Serum ferritin measured at the end of follow‐up</p> </li> <li> <p>Peak oxygen consumption (VO<sub>2</sub> peak or VO<sub>2</sub> max), as measured by cardiopulmonary exercise testing taken at the end of follow‐up </p> </li> <li> <p>Risk of bacterial infections. We included this outcome from studies where there was a clear definition of how a bacterial infection was detected and where measurement occurred equally in both groups. </p> </li> <li> <p>Risk of serious adverse events at the end of follow‐up, defined as any event that would increase mortality; were life‐threatening; required inpatient hospitalisation or resulted in persistent or significant disability; or any important medical events that might jeopardise the participant or that required intervention to prevent them within 30 days of cessation of treatment (<a href="./references#CD013084-bbs2-0075" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation and ICH Guidelines. Parexel Barnett: Media, 1996. ">ICH‐GCP 1996</a>). </p> </li> <li> <p>Risk of mild adverse events at the end of follow‐up, defined as any event that did not meet the definition of a serious adverse event but that required treatment or resulted in patient discomfort. Examples include headache, rash or nausea. We included hypophosphataemia of any severity in this category. </p> </li> </ol> </p> <section id="CD013084-sec-0051"> <h6 class="title">Information size calculation</h6> <p>For all meta‐analyses performed, we used Trial Sequential Analysis software (<a href="./references#CD013084-bbs2-0061" title="Copenhagen Trial Unit, Centre for Clinical Intervention Research. Trial Sequential Analysis. Version 0.9.5.5 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016. ">Copenhagen Trial Unit 2016</a>), in order to consider the adequacy of the power (<a href="./references#CD013084-bbs2-0076" title="ImbergerG , GluudC , BoylanJ , WetterslevJ . Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia and Analgesia2015;121:1611‐22. ">Imberger 2015</a>; <a href="./references#CD013084-bbs2-0087" title="MaschaEJ . Alpha, beta, meta: guidelines for assessing power and type I error in meta‐analyses. Anesthesia and Analgesia2015;121:1430‐3. ">Mascha 2015</a>). We used a type 1 error risk of 5% and a type 2 error risk of 10%, the pooled standard deviation for continuous data and unweighted mean of the control event rate for categorical data, and the diversity calculated from the actual meta‐analysis. </p> <p>Information size in meta‐analysis can be considered similar to an a priori power calculation for a planned RCT, powered to observe a particular magnitude of effect. We undertook hypothetical calculations for information size using G*Power v3.1 for each of the primary outcome measures. It should be noted that these calculations did not take into account inherent heterogeneity between studies. </p> <p> <ol id="CD013084-list-0008"> <li> <p>Overall quality of life, taken at the end of follow‐up: <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> described mental quality‐of‐life scores (SF‐12) taken at 56 days for intervention (47.3 ± 8.7) and control (45.1 ± 9.1). Based on this, an appropriately powered RCT to examine this effect size, with a type 1 error risk of 5% and a type 2 error risk of 10%, is 692. </p> </li> <li> <p>Concentration of haemoglobin, taken at the end of follow‐up: <a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> described haemoglobin concentration at 24 weeks for intervention (133 ± 1.0 g/L) and control (132 ± 1.0 g/L) groups. Based on this, an appropriately powered RCT to examine this effect size, with a type 1 error risk of 5% and a type 2 error risk of 10%, is 46. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD013084-sec-0052"> <h3 class="title">Search methods for identification of studies</h3> <p>In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status. </p> <section id="CD013084-sec-0053"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Injuries Group's Information Specialist searched the following databases on 18 October 2019: </p> <p> <ol id="CD013084-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (which contains the Cochrane Injuries Trials Register; CENTRAL; 2019, Issue 10) in the Cochrane Library (<a href="./appendices#CD013084-sec-0114">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to October 2019; <a href="./appendices#CD013084-sec-0115">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (1947 to October 2019; <a href="./appendices#CD013084-sec-0116">Appendix 3</a>); </p> </li> <li> <p>Web of Science: Science Citation Index Expanded (SCI‐EXPANDED; 1970 to October 2019; <a href="./appendices#CD013084-sec-0117">Appendix 4</a>); </p> </li> <li> <p>Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S; 1990 to October 2019; <a href="./appendices#CD013084-sec-0117">Appendix 4</a>); </p> </li> <li> <p>Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="./appendices#CD013084-sec-0118">Appendix 5</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; <a href="./appendices#CD013084-sec-0119">Appendix 6</a>). </p> </li> </ol> </p> </section> <section id="CD013084-sec-0054"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of all included studies and previous review articles for potential additional studies. </p> </section> </section> <section id="CD013084-sec-0055"> <h3 class="title" id="CD013084-sec-0055">Data collection and analysis</h3> <p>We conducted this review with adherence to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013084-bbs2-0071" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al(editors) . Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. ">Higgins 2019a</a>). </p> <p>We are aware that the wide range of intravenous iron preparations currently available implies that a network meta‐analysis could be considered more informative. However, the body of literature was not large enough to justify this approach. A future update of this review may uncover sufficient evidence to enable such an analysis. </p> <section id="CD013084-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LFM and EL) identified studies for inclusion independently of each other. We resolved any disagreement between review authors through discussion, or, if required, through involvement of a third review author (DS). We listed excluded studies along with the reason for exclusion. We investigated all eligible articles as full text. Where information in studies was unclear or missing we contacted the authors of individual studies directly for clarification and information. </p> </section> <section id="CD013084-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>Independent of one another, two review authors (LFM and EL) extracted data into a specifically‐designed and pilot‐tested form for this review, which included the following. </p> <p> <ol id="CD013084-list-0010"> <li> <p>Country of study participant recruitment</p> </li> <li> <p>Year and language of publication</p> </li> <li> <p>Year the study was conducted</p> </li> <li> <p>Study design</p> </li> <li> <p>Sample size</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Study population characteristics and clinical settings</p> </li> <li> <p>Iron therapy details, including dose, route, frequency and duration</p> </li> <li> <p>Study‐specific outcomes</p> </li> <li> <p>Outcomes included in this review</p> </li> <li> <p>Information to assess the risk of bias</p> </li> <li> <p>Details of prospective study registration</p> </li> <li> <p>Details of ethical review committee approval</p> </li> <li> <p>Sources of support and study funding</p> </li> </ol> </p> </section> <section id="CD013084-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed included studies for risk of bias according to the criteria outlined in Table 8.5.d in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013084-bbs2-0072" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. ">Higgins 2019b</a>). The domains used to assess the risk of bias were: selection bias (random sequence generation and allocation concealment); blinding bias (blinding of participants and personnel and blinding of outcome assessment); attrition bias (amount, nature and handling of incomplete outcome data); reporting bias (selective reporting of outcome data); other bias (bias not covered elsewhere such as source of funding bias). </p> <p>We categorised individual studies as being at low, high or unclear risk of bias overall according to the following criteria: </p> <p> <ol id="CD013084-list-0011"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results);</p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results); or</p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results).</p> </li> </ol> </p> </section> <section id="CD013084-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We used different treatment effects depending on the type of data. We calculated the mean difference (MD), with 95% confidence intervals (CIs), for continuous outcomes (e.g. iron store indices), and standardised mean difference (SMD) with 95% CIs for assessing treatment effect in quality of life (taking into account different scales used across studies). Subsequently, we transformed this into the quality‐of‐life measure used for the highest number of participants in the study, the Piper Fatigue Index. We used risk ratio (RR) with 95% CIs to measure treatment effects for dichotomous variables. </p> </section> <section id="CD013084-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant with iron deficiency who was undergoing treatment. As we did not consider cross‐over trials, we did not encounter any unit of analysis issues. </p> </section> <section id="CD013084-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We contacted all authors of the included studies with the aim of obtaining missing information. Where no response was forthcoming, we took the percentage of missing data into account when analysing and interpreting the results. If appropriate, we estimated any such data from available information using the mean value from the relevant group for the required outcome. For continuous measures, where possible we obtained SDs from other measures, such as standard errors (SEs), CIs, and P values. Where we were unable to extract any meaningful data, and it was not possible to estimate data, we necessarily excluded these studies. </p> <p>For dichotomous measures, we obtained proportions or percentages to estimate the number of events or participants assessed for that outcome. </p> </section> <section id="CD013084-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>Given a lack of common protocols used in research studies we expected a certain amount of clinical heterogeneity in the included studies. This was related to a number of factors but some potential sources of heterogeneity included variations in patient groups, different iron treatment regimens used and disparity in the quality of the study conduct. We used the Chi<sup>2</sup> test to explore heterogeneity of included studies with a significant alpha level of 0.10. We also measured heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD013084-bbs2-0070" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), to quantify inconsistencies and D<sup>2</sup> to adjust information size calculations as part of Trial Sequential Analysis (<a href="./references#CD013084-bbs2-0115" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9(86):e1‐12. ">Wetterslev 2009</a>). </p> <p>In addition to statistical assessments, we provided a descriptive assessment of heterogeneity as per the 'PICO' (population, intervention, comparison, outcome) model as part of the discussion. We expected heterogeneity in a number of areas, necessitating the use of a random‐effects model. Specific areas where heterogeneity was expected include the following. </p> <p> <ul id="CD013084-list-0012"> <li> <p>Population: we expected marked differences in population, ranging from otherwise healthy people (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>), to people with heart failure (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>). </p> </li> <li> <p>Intervention: we expected different preparations and dosages of iron. Whilst most modern treatment regimens contain fairly standardised dosages of elemental iron, we did not know what the effects of more historical preparations or regimens would be. </p> </li> <li> <p>Comparison: comparison was limited to placebo. We expected minimal heterogeneity.</p> </li> <li> <p>Outcomes: there was some heterogeneity due to differences in quality‐of‐life scores that the studies used. We hoped that the use of SMD would ameliorate some of this. </p> </li> </ul> </p> </section> <section id="CD013084-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>As there was fewer than 10 studies for all outcome measures, a formal assessment of publication bias using funnel plots, and subsequently Egger's test (<a href="./references#CD013084-bbs2-0063" title="EggerM , Davey‐SmithG ,  SchneiderM ,  MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629. ">Egger 1997</a>) was not possible. </p> </section> <section id="CD013084-sec-0064"> <h4 class="title">Data synthesis</h4> <p>If there were two or more studies with data for our defined outcomes, and data were sufficiently homogeneous, we performed a meta‐analysis. We used the software package Review Manager 5 (<a href="./references#CD013084-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We calculated the effect estimate using a random‐effects model. We pooled data using the Mantel‐Haenszel technique and subsequently assessed these outcomes using RRs. We pooled continuous variables using the inverse variance method, and reported results as mean ± SD. </p> <p>We considered the estimate of heterogeneity in our interpretation of the results, including an assessment of how the quantity of heterogeneity, and its source, may have affected the reliability of our conclusions. </p> <p>Where studies used difference scales for the assessment of continuous outcomes (i.e. quality‐of‐life score), we used SMD, with a subsequent transformation back into a single outcome measure. Due to the heterogeneity of scoring systems and population, we arbitrarily elected to present the data as the score used by the highest number of participants included in the meta‐analysis (Piper Fatigue Scale). </p> <p>When studies used a lower score to indicate superiority (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>), we transformed it to a positive integer for statistical analysis by multiplying the mean effect by −1. </p> </section> <section id="CD013084-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following three subgroup analyses if there were more than two studies included in each analysis. We performed the subgroup analyses for three categories of participant. </p> <p> <ol id="CD013084-list-0013"> <li> <p>Underlying pathology: participants who received iron as part of a treatment regimen for heart failure. Given that a single article dealt with a post‐operative population, but this population was cardiac‐specific, we elected to classify this study as pertaining to heart failure (<a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>). </p> </li> <li> <p>Underlying pathology: participants who were not otherwise classified into a pathology‐specific category by the original protocol. These included athletes, participants with restless leg syndrome, and otherwise well participants. </p> </li> <li> <p>Time to follow‐up: we stratified this to those participants who completed follow‐up at less than 10 weeks, as opposed to more than 10 weeks. </p> </li> </ol> </p> </section> <section id="CD013084-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct a sensitivity analysis on the primary outcome for each of the main analyses, by excluding any studies that demonstrated high or unclear risk of bias in any of the five domains. We also planned to assess the impact of any study that had a large effect size on the results of the meta‐analysis, and assessed the effects of missing data (<a href="#CD013084-sec-0061">Dealing with missing data</a>). However, given the low or very low quality of the evidence assessed, and the relatively small number of studies included in the review, we elected not to perform this analysis. </p> <section id="CD013084-sec-0067"> <h5 class="title">Trial Sequential Analysis</h5> <p>We performed Trial Sequential Analysis to preserve the risk of type 1 and type 2 errors at desired levels in the setting of sparse data and potential repeated testing (<a href="./references#CD013084-bbs2-0115" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9(86):e1‐12. ">Wetterslev 2009</a>). For all meta‐analyses performed, we used Trial Sequential Analysis (<a href="./references#CD013084-bbs2-0061" title="Copenhagen Trial Unit, Centre for Clinical Intervention Research. Trial Sequential Analysis. Version 0.9.5.5 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016. ">Copenhagen Trial Unit 2016</a>), in order to consider the adequacy of the power and to adjust the 95% confidence intervals if the data were sparse (<a href="./references#CD013084-bbs2-0076" title="ImbergerG , GluudC , BoylanJ , WetterslevJ . Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia and Analgesia2015;121:1611‐22. ">Imberger 2015</a>; <a href="./references#CD013084-bbs2-0087" title="MaschaEJ . Alpha, beta, meta: guidelines for assessing power and type I error in meta‐analyses. Anesthesia and Analgesia2015;121:1430‐3. ">Mascha 2015</a>). Preserving a type 1 error risk of 5% and a type 2 error risk of 10%, we constructed monitoring boundaries using the pooled SD for continuous data and the unweighted mean of the control event rate for categorical data, and the diversity calculated from the actual meta‐analysis. </p> </section> <section id="CD013084-sec-0068"> <h5 class="title">Summary of findings and assessment of the certainty of the evidence</h5> <p>We have presented the results of this review for all comparisons in a 'Summary of findings' table. We included the following outcomes. </p> <p> <ol id="CD013084-list-0014"> <li> <p>Mean difference in concentration of haemoglobin (g/L), taken at the end of follow‐up</p> </li> <li> <p>Standardised mean difference in quality‐of‐life scores in health‐related quality of life. We 'back‐translated' these into the Piper Fatigue Score for presentation. </p> </li> <li> <p>Mean difference in ferritin (µg/L), taken at the end of follow‐up</p> </li> <li> <p>Mean difference in incidence of bacterial infection</p> </li> <li> <p>Mean difference in peak oxygen consumption (VO<sub>2</sub> peak or VO<sub>2</sub> max), taken at the end of follow‐up </p> </li> <li> <p>Risk of serious adverse events (anaphylaxis, circulatory collapse, hospitalisation)</p> </li> <li> <p>Risk of mild adverse events (headache, dizziness, rash, hypophosphataemia)</p> </li> </ol> </p> <p>We prepared the 'Summary of findings' table using GRADEpro GDT software (<a href="./references#CD013084-bbs2-0069" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 14 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>). In accordance with the GRADE approach we undertook an assessment of the quality of evidence for each outcome. We examined the risk of bias within studies, directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias, and assessed the quality of evidence as either high, moderate, low or very low (<a href="./references#CD013084-bbs2-0109" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. ">Schünemann 2019</a>). </p> <p>In particular, we considered the appropriateness of extrapolating our results from all participants with iron deficiency to the perioperative setting and how the indirectness in this interpretation is likely to decrease the certainty in our results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013084-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013084-sec-0069"></div> <section id="CD013084-sec-0070"> <h3 class="title">Description of studies</h3> <section id="CD013084-sec-0071"> <h4 class="title">Results of the search</h4> <p>The search conducted by the Cochrane Injuries Group Information Specialist yielded 2582 references. After de‐duplication and reviewing the reference lists of the included articles we screened the study reports for inclusion. Following primary screening, we selected 61 articles for full‐text screening, and ultimately included 11 studies in qualitative and quantitative analysis (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> </section> <section id="CD013084-sec-0072"> <h4 class="title">Included studies</h4> <section id="CD013084-sec-0073"> <h5 class="title">Population</h5> <p>The 11 included studies provided 1074 participants. Of these studies, five examined a heart failure cohort (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>), two examined elite athletes (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), two examined otherwise well, pre‐menopausal women (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>), one examined people with restless legs syndrome (<a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>), and one examined a post‐operative cardiac surgical cohort (<a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>). All included studies were RCTs of intravenous iron preparations versus placebo. All studies were available through database searches as full manuscripts, with the exception of <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>, which was a conference extract. </p> <p>The studies used different definitions of iron deficiency depending on the study and population (<a href="#CD013084-tbl-0002">Table 1</a>). </p> <div class="table" id="CD013084-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study populations and definitions of iron deficiency</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition of iron deficiency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elite athletes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 30 mcg/L for women and &lt; 40 mcg/L for men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐menopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 15 mcg/L or &lt; 50mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 45 mcg/L</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐menopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 50 mcg/L</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elite athletes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin 30‐100 mcg/L</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013084-sec-0074"> <h5 class="title">Intervention</h5> <p>Studies used a variety of different treatment regimens for the administration of the study drug (<a href="#CD013084-tbl-0003">Table 2</a>). Five studies (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>) used a single administration, whilst six (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), used repeat dosing at various points throughout the study. Ferric carboxymaltose was the preferred iron preparation in eight studies (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), iron sucrose in two studies (<a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>), and iron isomaltoside in one (<a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>). The total dose of administered iron where calculation was possible ranged between 300 mg (<a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), up to 2500 mg (<a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>). </p> <div class="table" id="CD013084-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Iron preparations and dosing regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preparation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly until replete, then monthly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron isomaltoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>608 ± 204 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five doses over two weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron isomaltoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four doses over two weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly until replete, then monthly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500‐1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Six‐weekly until week 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two‐weekly for four weeks</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013084-sec-0075"> <h5 class="title">Comparator</h5> <p>Most included studies used 0.9% sodium chloride as a placebo comparator. Two studies were open‐label interventions (<a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>). Studies used variable blinding to conceal the characteristic reddish‐brown colour of iron‐containing solutions. We discuss these in the 'Risk of bias' discussion for individual studies. </p> </section> <section id="CD013084-sec-0076"> <h5 class="title">Outcome</h5> <p>Time to end of follow‐up differed substantially between included studies, and ranged from between 2 to 24 weeks (<a href="#CD013084-tbl-0004">Table 3</a>). </p> <div class="table" id="CD013084-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Duration of follow‐up after study drug administration</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>End of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 6</p> </td> </tr> </tbody> </table> </div> <p>With respect to primary outcome, five studies aimed to improve various quality‐of‐life scoring systems (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>), three aimed to optimise Hb concentration or total Hb mass (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), and two aimed to improve VO<sub>2</sub> peak or other markers of exercise capacity (<a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>). Whilst <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> did have VO<sub>2</sub> and quality of life available as outcome metrics, they did not present subgroup results for non‐anaemic participants. </p> <p>For the majority of outcomes specified a priori, data were expressed as mean ± SD. Where data were expressed as mean ± SD for baseline participant characteristics, and were subsequently reported as change in variable from baseline, these outcomes were necessarily excluded (<a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>). Where data were expressed graphically and not numerically, we contacted the study authors to request these data. Where we were unable to obtain the information, we excluded these outcomes too (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). </p> </section> </section> <section id="CD013084-sec-0077"> <h4 class="title">Excluded studies</h4> <p>After selection for full‐text screening, we excluded 50 articles for ineligible patient population, ineligible study design, ineligible route of administration, not measuring outcomes of interest or ineligible comparator. </p> <p>We identified some studies as containing information on the relevant population and outcomes that study authors could potentially extract so we could include them in the review. Where our attempts to contact the study authors were unsuccessful, and we could extract no further relevant data without the assistance of the study authors, we had to exclude these studies (<a href="./references#CD013084-bbs2-0017" title="BoomershineCS , KochTA , MorrisD . A blinded, randomized, placebo‐controlled study to investigate the efficacy and safety of ferric carboxymaltose in iron‐deficient patients with fibromyalgia. Rheumatology &amp; Therapy2018;5(1):271‐81. ">Boomershine 2018</a>; <a href="./references#CD013084-bbs2-0023" title="FilippatosG , FarmarkisD , Comin‐ColetJC , DicksteinK , LuscherTF , WillenheimerR , et al. Intravenous ferric carboxymaltose in iron‐deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR‐HF trial. European Journal of Heart Failure2013;15:1267‐76. ">Filippatos 2013</a>; <a href="./references#CD013084-bbs2-0025" title="FontanaS , JuniP , NiederhauserC , KellerP . Lack of effectiveness of intravenous iron infusion in healthy blood donors with low ferritin: a double‐blind randomized controlled trial. Vox Sanguinis2014;107(Suppl 1):98. ">Fontana 2014</a>; <a href="./references#CD013084-bbs2-0031" title="Gybel‐BraskM , SeebergJ , ThomsenLl , JohanssonPI . Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron‐deficient blood donors: a randomized double‐blind placebo‐controlled clinical trial. Transfusion2018;58:974‐81. ">Gybel‐Brask 2018</a>; <a href="./references#CD013084-bbs2-0046" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA . Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: a randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD013084-bbs2-0047" title="VanCraenenbroeckEM , ConraadsVM , GreenlawN , GaudesiusG , MoriC , PonikowskiP , et al. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR‐HF study. European Journal of Heart Failure2013;15:756‐62. ">Van Craenenbroeck 2013</a>). The reasons for exclusion of full‐text articles is listed in the PRISMA flowchart for this review (<a href="./references#CD013084-bbs2-0092" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>; <a href="#CD013084-fig-0001">Figure 1</a>), and in <a href="./references#CD013084-sec-0128" title="">Characteristics of excluded studies</a>. </p> <div class="figure" id="CD013084-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of studies included in the systematic review" data-id="CD013084-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of studies included in the systematic review</p> </div> </div> </div> </section> </section> <section id="CD013084-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>Graphical representations of risk of bias are shown in <a href="#CD013084-fig-0002">Figure 2</a> and <a href="#CD013084-fig-0003">Figure 3</a>. The assessment of risk of bias is individually displayed for each included study in <a href="#CD013084-fig-0002">Figure 2</a> and proportionally ranked for each 'Risk of bias' indicator in <a href="#CD013084-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013084-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013084-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <div class="figure" id="CD013084-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD013084-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013084-sec-0079"> <h4 class="title">Allocation</h4> <p>We did not consider any included studies at high risk of selection bias. However, we considered five of the included studies at unclear risk of selection bias due to poorly specified or unspecified randomisation schedules (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>), and five due to poorly specified or unspecified allocation concealment (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). Four studies had unclear risk of bias for both selection bias domains (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). We judged the remaining studies to be at low risk of selection bias in both random sequence generation and allocation concealment domains (<a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>). </p> </section> <section id="CD013084-sec-0080"> <h4 class="title">Blinding</h4> <section id="CD013084-sec-0081"> <h5 class="title">Performance bias</h5> <p>Due to the distinct colour of iron‐containing solutions, blinding of participants and personnel must necessarily involve the use of opaque syringes or administration bags and tubing to prevent performance bias. Three of the included studies were at high risk performance bias. Two of these were open‐label studies (<a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>), and one did not blind the study investigators and the use of opaque administration sets was unclear (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). We considered two studies at unclear risk of performance bias (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>), as these studies stated that they were blinded, but did not specifically reference the techniques they used in the study. The remaining six studies specifically referred to the use of concealed study drug administration and we considered them at low risk of performance bias (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> </section> <section id="CD013084-sec-0082"> <h5 class="title">Detection bias</h5> <p>We did not consider any of the included studies at high risk of detection bias. We considered four studies at unclear risk of detection bias as they did not explicitly state separation of outcome assessors from study drug administration in the manuscript (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>). We judged the remaining studies (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>) to be at low risk of detection bias. </p> </section> </section> <section id="CD013084-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>We did not consider any studies at high risk of attrition bias. We considered outcome reporting to be complete with a low risk of bias in eight studies (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>). We considered three studies at unclear risk of attrition bias because they only displayed relevant data in graphical form (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> </section> <section id="CD013084-sec-0084"> <h4 class="title">Selective reporting</h4> <p>We considered four studies at high risk of reporting bias due to failure to report baseline or follow‐up data for prespecified outcomes (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>). Three studies reported all outcomes specified in the study methods and we considered them at low risk of reporting bias (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>). The risk of bias was unclear in four studies as there was inadequate information to determine if they had reported all relevant data, or they had reported data as specified in the protocol but in a form not amenable to extraction (<a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> </section> <section id="CD013084-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>Nine studies received some form of pharmaceutical company support. In four of these, a study author was a direct employee of the company in question, and we assessed the study as high risk of bias (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>). We assessed the risk of bias in the remaining five studies as unclear (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a>). Two studies had no pharmaceutical company involvement and we assessed them as low risk of bias (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> </section> </section> <section id="CD013084-sec-0086"> <h3 class="title" id="CD013084-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD013084-tbl-0001"><b>Summary of findings for the main comparison</b> Intravenous iron compared to placebo for non‐anaemic, iron‐deficient adults</a> </p> <p>The summary of findings for the full study population is displayed in <a href="./full#CD013084-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD013084-sec-0087"> <h4 class="title">Primary outcomes</h4> <section id="CD013084-sec-0088"> <h5 class="title">Haemoglobin concentration</h5> <p>Eight studies reported haemoglobin concentration at the end of follow‐up (<a href="./references#CD013084-fig-0004" title="">Analysis 1.1</a>). Meta‐analysis suggested that the mean difference in haemoglobin concentration taken at the end of follow‐up was 3.04 g/L higher in the intervention group (95% CI 0.65 to 5.42; I<sup>2</sup> = 42%; 8 studies, 548 participants). We rated the overall quality of evidence for this outcome as 'low' according to GRADE criteria. Consequently, whilst intravenous iron may result in a small (and likely clinically insignificant) increase in haemoglobin taken at the end of follow‐up, our confidence in the effect estimate is limited. </p> <p> <ol id="CD013084-list-0015"> <li> <p>Risk of bias: none of the included studies were at low risk of bias, and two were unblinded. However, as loss to follow‐up was minimal, and the outcome is entirely objective, we did not downgrade the evidence level. </p> </li> <li> <p>Inconsistency: we noted moderate statistical heterogeneity (I<sup>2</sup> = 42%). There were multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up. We downgraded the evidence one level. </p> </li> <li> <p>Indirectness: whilst the included studies examined multiple different populations, these were consistent with the study question. The intervention, comparator and outcome were consistent across the included studies. We did not downgrade the evidence level. </p> </li> <li> <p>Imprecision: the confidence interval around the point prevalence estimate of effect is wide, and on Trial Sequential Analysis, the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. We downgraded the evidence one level. </p> </li> </ol> </p> </section> <section id="CD013084-sec-0089"> <h5 class="title">Quality of life</h5> <p>Three studies reported overall quality of life measured at the end of follow‐up (<a href="./references#CD013084-fig-0005" title="">Analysis 1.2</a>). Meta‐analysis suggested that the SMD of quality‐of‐life scores was 0.35 points higher in the intervention group at the end of follow‐up (95% CI 0.14 to 0.57 higher). We converted this back to the quality‐of‐life scoring system used by the largest number of participants in the included studies, Piper Fatigue Scale (<a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>). Using this metric, intravenous iron had a mean difference in Piper Fatigue Scale 0.73 points lower (95% CI 0.29 to 1.18 points lower; I<sup>2</sup> = 0%; 3 studies, 344 participants). We rated the overall quality of evidence for this conclusion as 'very low' according to GRADE criteria. Consequently, we are uncertain about the effect of intravenous iron on quality‐of‐life scoring taken at the end of follow‐up. </p> <p> <ol id="CD013084-list-0016"> <li> <p>Risk of bias: none of the included studies were at a low risk of bias, and we judged the largest included study to be at high risk of bias from multiple protocol deviations and no reporting of the per protocol analysis. We downgraded the evidence two levels. </p> </li> <li> <p>Inconsistency: we saw negligible statistical heterogeneity as reflected by the I<sup>2</sup> statistic value. There were multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up. Accordingly, we downgraded the evidence one level. </p> </li> <li> <p>Indirectness: whilst the included studies examined multiple different populations, these were consistent with the study question. The intervention, comparator and outcome were consistent across the included studies. Accordingly, we did not downgrade the evidence level. </p> </li> <li> <p>Imprecision: the generated effect size falls considerably short of a conservatively estimated effect size to deliver appropriate statistical power. We downgraded the evidence one level. </p> </li> </ol> </p> </section> </section> <section id="CD013084-sec-0090"> <h4 class="title">Secondary outcomes</h4> <section id="CD013084-sec-0091"> <h5 class="title">Ferritin concentration</h5> <p>Seven studies reported ferritin concentration at the end of follow‐up. The pooled results of this meta‐analysis were typified by extreme statistical heterogeneity, and wide confidence intervals, with marked differences in means and SDs between the included studies. This is due to differences in definition of iron deficiency, differences in iron regimen and differences to time to end of follow‐up. Consequently, we have not presented a pooled analysis of ferritin concentration as part of this review. Nevertheless, in all seven studies, we observed a higher ferritin concentration in the intervention group relative to the control. We undertook a subgroup analysis for this outcome based on underlying pathology (<a href="./references#CD013084-fig-0006" title="">Analysis 1.3</a>; see also 'Exploration of heterogeneity' section below). We undertook a GRADE assessment of the quality of evidence despite not presenting a global pooled result for this outcome. </p> <p> <ol id="CD013084-list-0017"> <li> <p>Risk of bias: none of the included studies were at low risk of bias, and one was unblinded. However, as loss to follow‐up is minimal and the outcome is entirely objective, we did not downgrade the quality of evidence. </p> </li> <li> <p>Inconsistency: we observed substantial statistical heterogeneity in the pooled result (I<sup>2</sup> = 100%). There were multiple points of methodological heterogeneity, with dose of iron administered and time to end of follow‐up. We downgraded the evidence two levels. </p> </li> <li> <p>Indirectness: whilst the included studies examined multiple different populations, these were consistent with the study question. Intervention, comparator and outcome were consistent across the included studies. We did not downgrade the evidence level. </p> </li> <li> <p>Imprecision: the point prevalence estimates in each of the included studies are highly imprecise, as reflected by the large confidence interval of the total result. The generated effect size is considerably less than the required effect size calculated by Trial Sequential Analysis. We downgraded the evidence two levels. </p> </li> </ol> </p> </section> <section id="CD013084-sec-0092"> <h5 class="title">Peak oxygen consumption</h5> <p>Only two studies reported peak oxygen consumption (VO<sub>2</sub> peak or VO<sub>2</sub> max) measured at the end of follow‐up (<a href="./references#CD013084-fig-0007" title="">Analysis 1.4</a>). Meta‐analysis suggested that the mean peak oxygen consumption taken at the end of follow‐up in the intervention group was 2.77 mL/kg/min higher (95% CI 0.89 lower to 6.43 higher; I<sup>2</sup> = 36%; 2 studies, 32 participants). We rated the overall quality of evidence for this conclusion as 'very low' according to GRADE criteria. Consequently, we are uncertain about the effect of intravenous iron on peak oxygen consumption taken at the end of follow‐up. </p> <p> <ol id="CD013084-list-0018"> <li> <p>Risk of bias: one of the two included studies was at high risk of bias for participant blinding. The outcome in question could potentially be compromised by performance bias, and we downgraded the evidence one level. </p> </li> <li> <p>Inconsistency: we observed minor statistical heterogeneity (I<sup>2</sup> = 36%). There were multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up. Accordingly, we downgraded the evidence one level. </p> </li> <li> <p>Indirectness: whilst the included studies examined multiple different populations, these were consistent with the study question. The intervention, comparator and outcome were consistent across the included studies. Accordingly, we did not downgrade the evidence level. </p> </li> <li> <p>Imprecision: the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. There is considerable difference in the mean point estimate of effect in the two included studies. We downgraded the evidence two levels. </p> </li> </ol> </p> </section> <section id="CD013084-sec-0093"> <h5 class="title">Incidence of mild to moderate adverse effects</h5> <p>Four studies reported incidence of mild to moderate adverse effects (<a href="./references#CD013084-fig-0008" title="">Analysis 1.5</a>). These referred to essentially participant‐reported side effects such as headache, fatigue and nausea. No studies reported data on hypophosphataemia. We did not consider adverse events that were unrelated to study drug administration (i.e. admission to hospital for exacerbation of heart failure) to be an adverse effect of study drug infusion. For example, we considered all adverse events in <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> to be unrelated to study drug administration, and so did not consider these data further. Meta‐analysis of the remaining three studies suggested that whilst intravenous iron was associated with a point prevalence increase in the risk of mild to moderate adverse events (RR 1.19, 95% CI 0.97 to 1.45; I<sup>2</sup> = 0%; 3 studies, 440 participants), the test for subgroup differences did not reveal a statistically significant difference between the subgroups. We rated the overall quality of evidence for this conclusion as 'very low' according to GRADE criteria. Consequently, we are uncertain about the effect of intravenous iron on the incidence of mild to moderate adverse effects taken at the end of follow‐up. </p> <p> <ol id="CD013084-list-0019"> <li> <p>Risk of bias: the largest included study was at high risk for participant blinding, and had multiple protocol deviations. Most side effects were qualitative, with no objective verification. We downgraded the evidence one level. </p> </li> <li> <p>Inconsistency: we observed minimal statistical heterogeneity (I<sup>2</sup> = 0%) but noted methodological heterogeneity regarding the dose of iron administered and the time to end of follow‐up. We downgraded the evidence one level. </p> </li> <li> <p>Indirectness: whilst the included studies examined multiple different populations, these were consistent with the study question. Intervention, comparator and outcome were consistent across the included studies. We did not downgrade the evidence quality. </p> </li> <li> <p>Imprecision: the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. There is a relatively consistent difference in the mean difference in the three included studies. We downgraded the evidence one level. </p> </li> </ol> </p> </section> <section id="CD013084-sec-0094"> <h5 class="title">Bacterial infection</h5> <p>Only one study (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>), recorded data on the incidence of bacterial infection. As we were not able to separate data for anaemic and non‐anaemic participants for this outcome for this study, we were not able to draw conclusions about these data. </p> </section> <section id="CD013084-sec-0095"> <h5 class="title">Incidence of severe adverse effects</h5> <p>No studies reported any serious adverse events.</p> </section> </section> <section id="CD013084-sec-0096"> <h4 class="title">Exploration of heterogeneity using subgroup analysis</h4> <p>We specified a number of different subgroup analyses a priori (<a href="#CD013084-sec-0065">Subgroup analysis and investigation of heterogeneity</a>). As specified in the protocol (<a href="./references#CD013084-bbs2-0117" title="MilesLF , LittonE , ImbergerG , StoryD . Intravenous iron therapy for non‐anaemic iron deficient adults. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD013084] ">Miles 2018b)</a>, we undertook subgroup analyses differentiating between underlying pathology and time to end of follow‐up (less than 10 weeks versus 10 weeks or more). We did not undertake a planned subgroup analysis based on type of iron deficiency because studies included in the functional iron deficiency group all used a combination definition of iron deficiency, including a patient population who, on the basis of the inclusion criteria specified a priori, would have met criteria for both functional and absolute iron deficiency. It was not possible to separate these data, nor were data presented on the relative proportions of absolute and functional iron deficiency in these studies. </p> <section id="CD013084-sec-0097"> <h5 class="title">Underlying pathology</h5> <p>A sufficient number of studies were available to perform analyses for haemoglobin concentration at the end of follow‐up (<a href="./references#CD013084-fig-0004" title="">Analysis 1.1</a>), and ferritin concentration at the end of follow‐up (<a href="./references#CD013084-fig-0006" title="">Analysis 1.3</a>). </p> <section id="CD013084-sec-0098"> <h6 class="title">Haemoglobin concentration at the end of follow‐up</h6> <p>Participants with heart failure demonstrated a modest improvement in haemoglobin concentration at the end of follow‐up (MD 3.79 g/L, 95% CI 0.40 to 7.18; I<sup>2</sup> = 66%; 5 studies, 461 participants). Participants with other pathologies had a point prevalence difference suggesting a lower incrementation in haemoglobin concentration with lower heterogeneity (MD 1.41 g/L, 95% CI −3.36 to 6.18; I<sup>2</sup> = 0%; 3 studies, 87 participants), although the confidence intervals for this metric crossed 0 and P = 0.43. There is no statistically significant difference between these two groups. As previously mentioned, substantial confounding of this result was present, and the studies that examined heart failure as a pathology (with the addition of <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>), were also the studies that used functional iron deficiency as a definition (<a href="./references#CD013084-fig-0004" title="">Analysis 1.1</a>; <a href="#CD013084-tbl-0005">Table 4</a>). </p> <div class="table" id="CD013084-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in haemoglobin concentration meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference (g/L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>z‐score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 to 5.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 7.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.36 to 6.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of iron deficiency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 7.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.36 to 6.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013084-sec-0099"> <h6 class="title">Ferritin concentration at the end of follow‐up</h6> <p>Extreme statistical heterogeneity was demonstrated on the primary meta‐analysis for this outcome, preventing the publication of a pooled result. We hypothesised that because those studies that examined heart failure were more likely to include participants with functional iron deficiency, the higher starting ferritin in these participants would result in a higher ferritin level at the end of follow‐up, resulting in the aforementioned heterogeneity. To confirm this hypothesis, and following the published protocol for this review (<a href="./references#CD013084-bbs2-0117" title="MilesLF , LittonE , ImbergerG , StoryD . Intravenous iron therapy for non‐anaemic iron deficient adults. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD013084] ">Miles 2018b</a>), we proceeded to perform separate analyses for those studies that examined people with heart failure (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>), and those that examined 'other' populations (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a>; <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>). </p> <p>In those participants with heart failure, the results of the meta‐analysis suggested that intravenous iron resulted in an increase in serum ferritin (MD 268.94 µg/L, 95% CI 264.99 to 272.90; I<sup>2</sup> = 0%; 4 studies, 291 participants), relative to those participants with other pathologies (MD 59.94 µg/L, 95% CI −12.94 to 132.83; I<sup>2</sup> = 96%; 3 studies, 87 participants). The difference between these two groups was statistically significant at P = 0.01. However, the wide confidence intervals, the persistence of extreme statistical heterogeneity in the other‐populations group, and very low‐quality evidence means that we remain uncertain of the exact effect of intravenous iron on serum ferritin in this latter subgroup. However, some narrative synthesis of this evidence is possible, and may partially highlight the origin of this heterogeneity. <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> randomised elite athletes to receive intravenous iron or placebo. Both groups were similar at baseline with a serum ferritin of 20.3 ± 7.2 µg/L in the intravenous iron group and 19.3 ± 6.9 µg/L in the control group. At 24 hours, the intravenous iron group demonstrated an increase in serum ferritin to 70.7 ± 10.0 µg/L, but this level had returned to baseline by the end of follow‐up at four weeks (23.4 ± 4.0 µg/L). In contrast, serum ferritin fell over the course of the study in the placebo group to 15.1 ± 6.2 µg/L. These results stand in contrast to the other two studies in this subgroup. <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> (a study conducted in patients with restless legs syndrome), observed a sustained increase in serum ferritin (from 20.1 ± 11.9 µg/L to 118.4 ± 75.4 µg/L) in participants in the intravenous iron arm at 11 weeks after dosing. <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> (again conducted in elite athletes) observed a similar sustained increase in the intravenous iron arm, with serum ferritin increasing from 62.8 ± 21.9 µg/L to 127.0 ± 66.3 µg/L over four weeks. We performed a sensitivity analysis excluding the results of <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> from the subgroup analysis, which resulted in a drop in statistical heterogeneity to 32%, suggesting that this failure to maintain sustained incrementation was the source of the initial result. One potential mechanism for this finding was the dosing strategy used by <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> (<a href="#CD013084-tbl-0003">Table 2</a>): in contrast to <a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> and <a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a>, <a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> used a single dose of intravenous iron instead of multiple doses over the course of study. On the basis of the current available evidence, it is not possible to confirm the biological plausibility of this theory, and given the very low quality of the evidence as outlined above, we remain uncertain as to the exact effect of intravenous iron in facilitating a sustained increase in serum ferritin in patients with absolute iron deficiency (<a href="./references#CD013084-fig-0006" title="">Analysis 1.3</a>; <a href="#CD013084-tbl-0006">Table 5</a>). </p> <div class="table" id="CD013084-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in ferritin concentration meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference (µg/L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>z‐score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of iron deficiency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>269.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265.10 to 273.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.15 to 18.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD013084-sec-0100"> <h5 class="title">Time to follow‐up</h5> <p>A sufficient number of studies were available to perform an analysis for haemoglobin concentration at the end of follow‐up (<a href="./references#CD013084-fig-0009" title="">Analysis 2.1</a>). Sufficient studies were available to perform an analysis for ferritin concentration at the end of follow‐up, but due to the previously described issues with statistical heterogeneity, we did not perform it. We saw a similar point prevalence increase in haemoglobin concentration in participants who concluded follow‐up at less than 10 weeks (MD 2.90 g/L, 95% CI −2.16 to 7.96; I<sup>2</sup> = 0%' 4 studies, 80 participants) and participants who completed their follow‐up in more than 10 weeks (MD 3.37 g/L, 95% CI −0.02 to 6.76; I<sup>2</sup> = 72%; 4 studies, 468 participants). </p> </section> </section> <section id="CD013084-sec-0101"> <h4 class="title">Trial Sequential Analysis</h4> <p>We performed Trial Sequential Analysis to preserve the risk of type 1 and type 2 errors at desired levels in the setting of sparse data and potential repeated testing (<a href="./references#CD013084-bbs2-0115" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9(86):e1‐12. ">Wetterslev 2009</a>). For all primary meta‐analyses performed, we used Trial Sequential Analysis in order to consider the adequacy of the power and to adjust the 95% confidence intervals if the data were sparse (<a href="./references#CD013084-bbs2-0061" title="Copenhagen Trial Unit, Centre for Clinical Intervention Research. Trial Sequential Analysis. Version 0.9.5.5 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016. ">Copenhagen Trial Unit 2016</a>; <a href="./references#CD013084-bbs2-0076" title="ImbergerG , GluudC , BoylanJ , WetterslevJ . Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia and Analgesia2015;121:1611‐22. ">Imberger 2015</a>; <a href="./references#CD013084-bbs2-0087" title="MaschaEJ . Alpha, beta, meta: guidelines for assessing power and type I error in meta‐analyses. Anesthesia and Analgesia2015;121:1430‐3. ">Mascha 2015</a>). Preserving a type 1 error risk of 5% and a type 2 error risk of 10%, we constructed monitoring boundaries using the pooled SD for continuous data and the unweighted mean of the control event rate for categorical data, and the diversity calculated from the actual meta‐analysis. </p> <p>Using the assumptions described in our methods, the Trial Sequential Analyses showed that existing data are insufficient for all our outcomes to demonstrate a statistically significant result, despite our anticipated study power as per the calculated information size. </p> <p>For the comparison of intravenous iron with placebo on haemoglobin concentration at the end of follow‐up, the estimated required information size was 1068. The meta‐analysis included 596 participants and was therefore underpowered given the assumptions we used. The adjusted 95% CI for haemoglobin concentration at the end of follow‐up was −0.8 to 7.2 g/L, demonstrating the increased uncertainty present due to sparse data and no statistically significant increase in the group receiving iron. </p> <p>For the comparison of intravenous iron with placebo on quality‐of‐life scores, the estimated required information size was 1895. The meta‐analysis included 566 participants and was therefore underpowered given the assumptions we used. The adjusted 95% CI for participant‐centred outcomes was −3 to 8 points, demonstrating the increased uncertainty present due to sparse data. </p> <p>For the comparison of intravenous iron with placebo on ferritin concentration at the end of follow‐up, the estimated required information size was 2282. The meta‐analysis included 367 participants and was therefore underpowered given the assumptions we used. The adjusted 95% CI for ferritin concentration at the end of follow up was −440 to 779 μmol/L, demonstrating the increased uncertainty present due to sparse data and no statistically significant increase in the group receiving iron. </p> <p>For the comparison of intravenous iron with placebo on peak oxygen consumption at the end of follow‐up, the estimated required information size was 154. The meta‐analysis included 32 participants and was therefore underpowered given the assumptions we used. The adjusted 95% CI for peak oxygen consumption at the end of follow up was −6 to 12 mL/kg/min, demonstrating the increased uncertainty present due to sparse data. </p> <p>For the comparison of intravenous iron with placebo on mild to moderate adverse effects, the estimated required information size was 32,302. The meta‐analysis included 566 participants and was therefore underpowered given the assumptions we used. The data were too sparse for adjusted confidence intervals to be meaningful. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013084-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013084-sec-0102"></div> <section id="CD013084-sec-0103"> <h3 class="title" id="CD013084-sec-0103">Summary of main results</h3> <p>This review included 11 studies that compared intravenous iron with placebo across a range of patient populations. There was considerable variability in the dosing regimen, iron preparation and duration of follow‐up between studies. The dose per week of iron varied from 100 mg to 1000 mg, although multiple studies used a single‐dose model (six studies), as repeated dosing (five studies) that varied between individual participants depending on the study. </p> <p>Reporting of the primary outcome measures was variable, with eight studies reporting haemoglobin concentration at the end of follow‐up, and three studies reporting quality of life at the end of follow‐up. For the secondary outcome metrics, laboratory‐centred outcome metrics were relatively widely reported, specifically ferritin concentration (seven studies), peak oxygen consumption (two studies) and mild to moderate side‐effects (four studies). </p> <p>Intravenous iron may cause a small but ultimately clinically unimportant increase in haemoglobin concentration, but we assessed the quality of this evidence as low. The quality of evidence for quality‐of‐life scores was very low, so we are uncertain about the effects of intravenous iron on this outcome metric. With respect to secondary outcomes, we judged it inappropriate to present a pooled estimate for ferritin due to the extreme statistical heterogeneity. We hypothesised that this was due to differences in starting ferritin between those participants with heart failure (the constituent subgroup studies including participants with both absolute and functional and absolute iron deficiency) and those from other populations (the constituent subgroup studies including only participants with absolute iron deficiency). We evaluated these differences in a subgroup analysis that partially confirmed this hypothesis. However, severe statistical heterogeneity persisted in the other population subgroups, suggesting that there are confounding factors that remain undetected in this analysis. Ultimately, the very low level of evidence assigned to this outcome, and our lack of confidence in a robust estimate of differences between the groups, prevents us from making concrete finding on the precise effect of intravenous iron on serum ferritin concentration. We are similarly uncertain regarding the effects of intravenous iron on peak oxygen consumption, or mild to moderate side effects, again because of the very low quality of the evidence. The incidence of bacterial infection and severe adverse effects across all included studies was zero. </p> </section> <section id="CD013084-sec-0104"> <h3 class="title" id="CD013084-sec-0104">Overall completeness and applicability of evidence</h3> <p>Whilst the 11 included studies covered a wide range of patient populations, and met the inclusion criteria that were specified a priori, we were ultimately prevented from reaching robust conclusions as to the role of intravenous iron in the treatment of non‐anaemic iron deficiency, despite biological plausibility. This was due to the often severe statistical and methodological heterogeneity evident in many of the pooled analyses. We encountered further difficulties when considering the reporting of outcome measures. Studies frequently reported outcomes in different ways, resulting in their exclusion from the meta‐analysis, despite our efforts to contact the relevant study authors. </p> <p>The included studies were also affected by multiple methodological differences, related to the population studied, the definition of iron deficiency used, the preparation of intravenous iron, the dose and the frequency of the study drug. Further confounding was evident on subgroup analysis, with those studies that used a functional iron deficiency definition (<a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a>; <a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a>; <a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a>; <a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a>; <a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a>), also including participants who met diagnostic criteria for absolute iron deficiency. However, while these considerations make drawing firm conclusions from this review difficult, it does provide important insights into the differing approaches used by various study authors, and the challenges faced by clinicians when attempting to apply this evidence to the individual patient. This is a problem that has been encountered by authors of best practice guidelines previously; for example, <a href="./references#CD013084-bbs2-0095" title="MuñozM , AchesonAG , AuerbachM , BesserM , HablerI , KehletH , et al. International consensus statement on the peri‐operative management of anaemia and iron deficiency. Anaesthesia2017;72:233‐47. ">Muñoz 2017</a> cited three different definitions of iron deficiency as part of their consensus statement before finally defining non‐anaemic iron deficiency as a TSAT less than 20%, without any reference to ferritin, a definition not encountered in any study screened as part of this review, included or excluded. This is not to say that the authors of these guidelines were incorrect in applying this definition, but that, as shown by this review, there is currently limited evidence as to which form of iron deficiency, and which population would benefit most from receiving this treatment. </p> </section> <section id="CD013084-sec-0105"> <h3 class="title" id="CD013084-sec-0105">Quality of the evidence</h3> <p>We graded the overall quality of evidence for the various laboratory outcomes in the review as 'low' or 'very low' (<a href="./full#CD013084-tbl-0001">summary of findings Table for the main comparison</a>). For the most part this was due to inconsistency, manifested by considerable statistical heterogeneity, and imprecision, manifested by failure to reach an appropriate sample size (as demonstrated by Trial Sequential Analysis). Differences in length of follow‐up and dosing regimen contributed to the statistical heterogeneity identified in the meta‐analysis. Despite apparent biological plausibility for certain outcomes, and point prevalence estimates and confidence intervals that, in and of themselves, would appear to be suggestive of an effect, the low quality of the evidence means that we are uncertain about the effect of intravenous iron on most of the outcomes presented in this review. </p> <p>For participant‐centred and adverse effect outcome metrics, the subjective nature of the reported outcomes and the risk of performance bias in several studies was an additional factor in the substantial downgrading of evidence, together with the inconsistency and imprecision identified above. </p> <p>The factors identified above substantially reduce our confidence in the body of evidence considered as part of this review. </p> </section> <section id="CD013084-sec-0106"> <h3 class="title" id="CD013084-sec-0106">Potential biases in the review process</h3> <p>A key review decision taken following the consideration of the study data was to alter the inclusion criteria around the definition of a non‐anaemic status. This may have resulted in underreporting of the indirectness of the included studies relative to the original research question, whereby the indirectness of the included studies would have been inadequately considered. </p> <p>Even with the change in the study inclusion criteria outlined above, there remain a low number of studies included in this review, and according to the specifications outlined in our original protocol we are unable to make a judgement on publication bias (<a href="./references#CD013084-bbs2-0117" title="MilesLF , LittonE , ImbergerG , StoryD . Intravenous iron therapy for non‐anaemic iron deficient adults. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD013084] ">Miles 2018b</a>). Given the extensive involvement of pharmaceutical companies in studies examining this research question, we are unable to exclude the influence of publication bias on our review. </p> </section> <section id="CD013084-sec-0107"> <h3 class="title" id="CD013084-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of two other reviews that have examined similar research questions. In <a href="./references#CD013084-bbs2-0056" title="BurdenRJ , MortonK , RichardsT , WhyteGP , PedlarCR . Is iron treatment beneficial in iron‐deficient but non‐anaemic (IDNA) endurance athletes? A systematic review and meta‐analysis. British Journal of Sports Medicine2015;49:1389‐97. ">Burden 2015b</a>, the authors focused on elite athletes alone, and assessed the effects of multiple different routes of administration of iron on exercise capacity. The authors concluded in their review that, "iron treatments improve the iron status and aerobic capacity of iron deficiency non‐anaemic endurance athletes". No included studies in this review examined the effect of intravenous iron (being limited to intramuscular and oral iron alone). The authors subsequently published an RCT on the effect of intravenous iron in non‐anaemic, iron‐deficient elite athletes, which we included in our review (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>). </p> <p>In <a href="./references#CD013084-bbs2-0074" title="HoustonBL , HurrieD , GrahamJ , PerijaB , RimmerE , RabbaniR , et al. Efficacy of iron supplementation on fatigue and physical capacity in nonanaemic iron‐deficient adults: a systematic review of randomised controlled trials. BMJ Open2018;8(8):e019240. ">Houston 2018</a>, the authors examined the effect of oral, intramuscular and intravenous iron on fatigue and exercise capacity in adults. Whilst the review was limited to studies conducted in a primary care setting, it identified three studies (<a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a>; <a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a>; <a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a>), that utilised intravenous iron in this setting. Whilst the pooled results of all routes of administration led the authors to conclude that in non‐anaemic, iron‐deficient adults in a primary care setting, "iron supplementation is associated with reduced subjective measures of fatigue but not with objective improvements in physical capacity". This is broadly consistent with our own results for quality of life and peak oxygen consumption. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013084-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of studies included in the systematic review" data-id="CD013084-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of studies included in the systematic review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013084-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD013084-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous iron versus placebo (population), Outcome 1 Haemoglobin concentration taken at the end of follow‐up." data-id="CD013084-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intravenous iron versus placebo (population), Outcome 1 Haemoglobin concentration taken at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous iron versus placebo (population), Outcome 2 Overall quality of life measured at the end of follow‐up." data-id="CD013084-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intravenous iron versus placebo (population), Outcome 2 Overall quality of life measured at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous iron versus placebo (population), Outcome 3 Ferritin concentration taken at the end of follow‐up." data-id="CD013084-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intravenous iron versus placebo (population), Outcome 3 Ferritin concentration taken at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous iron versus placebo (population), Outcome 4 Peak oxygen consumption taken at the end of follow‐up." data-id="CD013084-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intravenous iron versus placebo (population), Outcome 4 Peak oxygen consumption taken at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous iron versus placebo (population), Outcome 5 Mild adverse effects." data-id="CD013084-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intravenous iron versus placebo (population), Outcome 5 Mild adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013084-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/urn:x-wiley:14651858:media:CD013084:CD013084-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_t/tCD013084-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous iron versus placebo (time to end of follow‐up), Outcome 1 Haemoglobin concentration taken at the end of follow‐up." data-id="CD013084-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intravenous iron versus placebo (time to end of follow‐up), Outcome 1 Haemoglobin concentration taken at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/media/CDSR/CD013084/image_n/nCD013084-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013084-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous iron compared to placebo for non‐anaemic, iron‐deficient adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous iron compared to placebo for non‐anaemic iron deficient adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐anaemic, iron‐deficient adults<br/> <b>Setting:</b> all healthcare settings (acute, subacute and community care)<br/> <b>Intervention:</b> intravenous iron<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intravenous iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin concentration</b> taken at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin concentration taken at the end of follow‐up was 131.93 g/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.04 g/L higher<br/> (0.65 higher to 5.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous iron may result in a slight, clinically insignificant increase in haemoglobin concentration taken at the end of follow‐up, but the evidence is limited. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall quality of life</b> measured at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall quality of life measured at the end of follow‐up was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Piper Fatigue Scale MD 0.73 lower (0.29 to 1.18 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on overall quality of life measured at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin</b> concentration measured at the end of follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>We were unable to perform meta‐analysis for this outcome due to substantial statistical heterogeneity (I<sup>2</sup> = 100%). In all 7 studies a we observed a higher ferritin concentration in the intervention group relative to the control </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on serum ferritin at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bacterial infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peak oxygen consumption</b> taken at the end of follow‐up </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean peak oxygen consumption taken at the end of follow‐up was 25.89 mL/kg/min</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.77 mL/kg/min higher<br/> (0.89 lower to 6.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of intravenous iron on peak oxygen consumption taken at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies reported any serious adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mild adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/> (0.97 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>440<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>4,7,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are uncertain about the effect of intravenous iron on mild to moderate adverse effects taken at the end of follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>402 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>478 per 1,000<br/> (390 to 583) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for inconsistency: there was moderate statistical heterogeneity and multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up.<br/> <sup>2</sup>Downgraded one level for imprecision: the confidence interval around the point prevalence estimate of effect is wide, and on Trial Sequential Analysis, the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power.<br/> <sup>3</sup>Downgraded one level for risk of bias: none of the included studies were at low risk of bias, and we judged the largest included study to be at high risk of bias from multiple protocol deviations and no reporting of the per protocol analysis.<br/> <sup>4</sup>Downgraded one level for inconsistency: despite mild or negligible statistical heterogeneity, we observed multiple points of methodological heterogeneity, with the dose of iron administered and the time to end of follow‐up.<br/> <sup>5</sup>Downgraded two levels for inconsistency: there was substantial statistical heterogeneity in the pooled result (I<sup>2</sup> = 100%) and multiple points of methodological heterogeneity, with dose of iron administered and time to end of follow‐up.<br/> <sup>6</sup>Downgraded two levels for imprecision: the point prevalence estimates in each of the included studies are highly imprecise, as reflected by the large confidence interval of the total result. The generated effect size is considerably less than the required effect size calculated by Trial Sequential Analysis.<br/> <sup>7</sup>Downgraded one level for risk of bias: one of the two included studies was at high risk of bias for participant blinding. The outcome in question could potentially be compromised by performance bias.<br/> <sup>8</sup>Downgraded two levels for imprecision: the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. There is considerable difference in the mean difference in the two included studies.<br/> <sup>9</sup>Downgraded one level for imprecision: on Trial Sequential Analysis, the generated effect size falls short of a conservatively estimated effect size to deliver appropriate statistical power. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intravenous iron compared to placebo for non‐anaemic, iron‐deficient adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013084-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study populations and definitions of iron deficiency</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition of iron deficiency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elite athletes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 30 mcg/L for women and &lt; 40 mcg/L for men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐menopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 15 mcg/L or &lt; 50mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 45 mcg/L</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐menopausal women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 50 mcg/L</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin &lt; 100 mcg/L or 100‐200 mcg/L where TSAT &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elite athletes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferritin 30‐100 mcg/L</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study populations and definitions of iron deficiency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013084-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Iron preparations and dosing regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preparation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly until replete, then monthly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron isomaltoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>608 ± 204 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five doses over two weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron isomaltoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four doses over two weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly until replete, then monthly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500‐1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Six‐weekly until week 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two‐weekly for four weeks</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Iron preparations and dosing regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013084-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Duration of follow‐up after study drug administration</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>End of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0001" title="AnkerSD , CominCJ , FilippatosJ , WillenheimerR , DicksteinK , DrexlerH , et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine2009;361:2436‐48. ">Anker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0002" title="BurdenRJ , PollockN , WhyteGP , RichardsT , MooreB , BusbridgeM , et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Medicine and Science in Sports and Exercise2015;47(7):1399‐407. ">Burden 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0003" title="Charles‐EdwardsG , AmarelN , SleighA , AyisA , CatibogN , McDonaghT , et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency ‐ FERRIC‐HF II randomized mechanistic trial. Circulation2019;139:2386‐98. ">Charles‐Edwards 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0004" title="FavratB , BalckK , BreymannC , HedenusM , KellerT , MezzacasaA , et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron‐deficient women‐‐PREFER a randomized, placebo‐controlled study. PloS One2014;9(4):e94217. ">Favrat 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0005" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009; Vol. 24, issue 10:1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0006" title="JohanssonPI , RasmussenAS , ThomsenLL . Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non‐anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double‐blind placebo‐controlled clinical trial (the PROTECT trial). Vox Sanguinis2015;109(3):257‐66. ">Johansson 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0007" title="KrayenbuehlPA , BattegayE , BreymannC , FurrerJ , SchulthessG . Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood2011; Vol. 118, issue 12:3222‐7. ">Krayenbuehl 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0008" title="OkonkoDO , GrzesloA , WitkowskiT , MandalAk , SlaterRM , RoughtonM , et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. Journal of the American College of Cardiology2008; Vol. 51, issue 2:103‐12. ">Okonko 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0009" title="VanVeldhuisenDJ , PonikowskiP , Van derMeerP , MetraM , BohmM , DoletskyA , et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation2017; Vol. 136:1374‐83. ">Van Veldhuisen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0010" title="WongC , NgA , LauJ , KritharidesL , SindoneA . Early responses to intravenous iron therapy in patients with chronic heart failure and iron deficiency. Heart, Lung &amp; Circulation2016;25 (Suppl 2):S107. ">Wong 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013084-bbs2-0011" title="WoodsA , Garvican‐LewisLA , SaundersPU , LovellG , HughesD , FazakerleyR , et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS ONE2014; Vol. 9, issue 9:e108042. ">Woods 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 6</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Duration of follow‐up after study drug administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013084-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in haemoglobin concentration meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference (g/L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>z‐score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 to 5.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 7.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.36 to 6.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of iron deficiency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 7.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.36 to 6.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in haemoglobin concentration meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013084-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in ferritin concentration meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean difference (µg/L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>z‐score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of iron deficiency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Functional iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>269.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265.10 to 273.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute iron deficiency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.15 to 18.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Subgroup analysis to examine heterogeneity in ferritin concentration meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/full#CD013084-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013084-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous iron versus placebo (population)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin concentration taken at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.65, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [0.40, 7.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Other populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [‐3.36, 6.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall quality of life measured at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.14, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ferritin concentration taken at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>165.72 [33.05, 298.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>268.94 [264.99, 272.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Other populations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.95 [2.69, 65.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Peak oxygen consumption taken at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [‐0.89, 6.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mild adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.97, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous iron versus placebo (population)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013084-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous iron versus placebo (time to end of follow‐up)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin concentration taken at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.65, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐2.16, 7.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &gt; 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [‐0.02, 6.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous iron versus placebo (time to end of follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013084.pub2/references#CD013084-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013084.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013084-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013084-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013084-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013084-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013084-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013084-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013084-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013084-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013084-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013084\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013084\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013084\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013084\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013084\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013084.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013084.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013084.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013084.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013084.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725730035"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013084.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725730039"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013084.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e825a9848936d',t:'MTc0MDcyNTczMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 